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Roles of Macrophage Mitochondrial Oxidative Stress and Mitochondrial Fission in Atherosclerosis 
Ying Wang 
Electron transportation (ET) coupled with oxidative phosphorylation (OXPHOS) in the 
mitochondria produces limited, physiologic levels of reactive oxygen species (ROS).   While this process 
is adaptive under normal conditions, excessive mitochondrial oxidative stress (mitoOS) has been 
correlated with a number of diseases, including atherosclerotic vascular disease in humans.  However, 
definitive evidence of causation and cell-specific pro-atherogenic mechanisms of mitoOS require further 
investigation.    
 The high level of interest in this topic, the human relevance, and the potential therapeutic 
implications prompted us to explore causation and mechanism with a focus on the key inflammatory cell 
type in atherosclerosis, the macrophage (Chapter 2).  For this purpose, we used a recently described 
model, the mitochondrial catalase (mCAT) transgenic mouse, that decreases mitoOS in vivo.  Normally, 
glutathione perioxidase is the endogenous mitochondrial enzyme that catalyzes the reduction of H2O2 and 
prevents its conversion into the most detrimental ROS hydroxyl nitrites.  Catalase can carry out this role in 
peroxisomes, where it is exclusively located.  The mCAT transgenic mouse expresses human catalase 
with a mitochondrial matrix-targeting motif, which quenches mitoOS and protects against mitoOS-induced 
damage.  To focus on myeloid-derived cells in atherosclerosis, we used two strategies:  transplantation of 
mCAT transgenic bone marrow cells into atheroprone Ldlr
-/-
 mice and crossing Ldlr
-/-
 mice with an 
mCAT
fl/-
LysMCre model that expresses mCAT only in lysozyme M-expressing cells, notably differentiated 
macrophages.  After 8 wk western type diet (WD) feeding, both models demonstrated evidence of 
decreased mitoOS in lesional macrophages, decreased atherosclerosis, suppression of Ly6c
hi
 monocyte 
infiltration, and lower levels of the monocyte chemotactic protein-1 (MCP-1).  The decrease in lesional 
MCP-1 was associated with suppression of other markers of inflammation (iNOS and TNF-α) and with 
decreased phosphorylation of the critical transcription factor RelA (NF-κB p65), indicating decreased 
activation of the pro-inflammatory NF-κB pathway.   Using models of mitoOS in cultured macrophages, 




NF-κB (RelA) pathway.  Taken together, we conclude that MitoOS in lesional macrophages amplifies 
early atherosclerotic lesion development by promoting NF-κB-mediated entry of monocytes and other 
inflammatory processes.  In view of the mitoOS-atherosclerosis link in human atheromata, these findings 
reveal a potentially new therapeutic target to prevent the early progression of atherosclerosis.      
 The mitochondrial dynamic processes of fission and fusion influence and integrate with multiple 
physiologic and pathophysiologic processes.  Mitochondrial fusion/fission dysregulation has been 
implicated in atherosclerosis, but little is known about the role of myeloid cell specific mitochondrial 
dynamics in the progression of atherosclerosis.  Dynamin related protein 1(DRP1), a cytosolic GTPase 
family member, is one of the molecules that mediate mitochondrial fission.  In the second part of this 






mice to determine the role of Mφ 
mitochondrial fission in both early atherogenesis and advanced atherosclerosis.  Our data thus far show 






mice by transmission 
electron microscopy (TEM) analysis; (2) Suppression of Mφ mitochondrial fission does not affect early 
atherogenesis; (3) Inhibition of Mφ mitochondrial fission leads to a striking increase of necrotic core area 
and the accumulation of apoptotic cells, which are likely due to the defective phagocytic clearance of 
apoptotic cells (efferocytosis) in the advanced stage of atherosclerosis in vivo; (4) DRP1-deficient Mφs 
are defective in efferocytosis in vitro and in vivo.  (5) The phagocytic deficiency in DRP1-deficient Mφs is 
associated with a reduced level of uncoupling protein 2 (UCP2), a mitochondria protein required for 
continuous uptake and clearance of dead cells in phagocytes.  We conclude that DRP1-mediated 
mitochondrial fission in Mφs promotes the clearance of apoptotic cells and thereby blocks necrotic core 
formation in advanced atherosclerosis.   This study indicates that mitochondrial fusion/fission could be a 
new therapeutic target to stabilize the advanced plaques and prevent acute atherothrombosis in humans.  
In terms of mechanism, we hypothesize that mitochondrial fission stabilizes UCP2 in the inner membrane 
of mitochondria.  Further studies are required to elucidate how DRP1-UCP2 pathway maintains the 
efferocytosis capability in phagocytosis. 
 In summary, my thesis studies have revealed the pathological significance of macrophage 
mitoOS in early atherogenesis and a novel link of mitochondria dynamics to macrophage phagocytosis in 
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* This chapter is a part of the article “Emerging roles of mitochondria ROS in atherosclerotic lesions: 
causation or association?  J Atheroscler Thromb, 2014.  The first author and corresponding author of this 






Mitochondrial Derived ROS and its regulation 
Mitochondrial reactive oxygen species (mtROS) are natural by-products of the electron 
transportation chain (ETC), a key step in the generation of ATP through oxidative phosphorylation 
(OXPHOS).
1
  In this process, as the electrons are shuttled through a group of protein complexes 
(complex I-V), electron leakage from Complex I and III results in partial reduction of oxygen and the 




 is then converted to an intermediate product hydrogen peroxide 
(H2O2) by matrix manganese superoxide dismutase (MnSOD, SOD2) or Cu/ZnSOD in the mitochondrial 
intermembrane space.  H2O2 is further reduced to H2O through glutathione peroxidase (GPX) and 
circulating reduced glutathione (GSH) and oxidized glutathione (GSSH).  This antioxidant system is 
essential for preventing the generation and accumulation of highly reactive products such as peroxynitrite 
(OONO-), a product of nitric oxide (NO) with O2•
-
, and hydroxal radical (•HO), a product of the Fenton 
reaction between Fe
2+
 with H2O2.  Consequently, this antioxidant system protects the mitochondria from 
mtROS-induced mtDNA damage, protein modification (oxidation and nitration), and lipid peroxidation 
under normal and pathological conditions.   
 Convincing evidence supports the concept that mtROS plays physiologic roles through second 
messenger generation and signal transduction reactions to maintain cellular homeostasis in the vascular 
wall.
2





  However, excessive mtROS has been implicated in pathophysiologic processes in 
humans and animal models, including cardiovascular, neurodegenerative diseases, and aging.
5-7
  The 
balance between mtROS generation and clearance controls mitochondrial oxidative status.  This balance 
is regulated by the mitochondria metabolic status, cross inner-membrane potential (ΔΨ), ETC complexes 
and antioxidant enzyme activities, uncoupling proteins (UCPs), components of mitochondrial fusion and 










Evidence of excessive mtROS in atherosclerotic lesions 
 Due to the physical proximity of mtDNA to ETC-derived ROS and the lack of protective histone or 
DNA repair mechanisms that occur in the nuclear genome, mtDNA is much more vulnerable to oxidative 
damage than genomic DNA.
8, 9
  8-OHdG (8-hydroxydeoxyguanosine) is one of the major DNA products 
formed upon oxidative damage of DNA in various pathological conditions.
10-13
  8-OHdG accumulation has 
been observed in circulating leukocytes and in various cell types in human and murine atherosclerotic 




 mice fed a high-fat Western-type 
diet (WD).
12-14
  In line with this finding, a 5-kb mtDNA deletion, referred to as “the common mtDNA 
deletion,” has been identified in mouse and human atherosclerotic lesions and was found to be closely 
associated with the extent of atherosclerosis.
15
 Furthermore, human and rabbit atherosclerotic lesions 
react with an antibody that recognizes an oxidized form of cardiolipin, a phospholipid exclusively 
expressed in mitochondria, suggesting excessive mtROS.
16
  Thus, several lines of evidence indicate that 
excessive mtROS-induced oxidative damage occurs in atherosclerotic lesions of both animal models and 
















Why does excessive mtROS occur in atherosclerosis? 
 Failure of mitochondrial antioxidant functions.  The antioxidant enzyme systems located in the 
inner membrane of mitochondria are the first line of defense against the excessive production of mtROS 
from ETC.  Emerging evidence supports the notion that in the early stages of disease development, 
antioxidant enzyme levels and activities are compensatorily enhanced to maintain redox homeostasis.  
However, as the disease progresses, antioxidant enzyme levels decline.
17-19
  With regard to 
atherosclerosis, the aortae of Apoe
-/-
 mice were shown to respond to atherogenic stimuli by an early 
increase and then subsequent decrease in the expression of antioxidant enzymes, including 
mitochondrial specific antioxidant GPX1 and SOD2.
19
  Similarly, MnSOD expression and parallel enzyme 
activities were reported to be enhanced only in viable cells, but not in apoptotic cells, in human 
atherosclerotic lesions.
17
  In advanced atherosclerosis or atherosclerosis accompanied with hemodialysis 
(HD), diabetes, and smoking, excessive mtROS is observed and is associated with a marked decrease in 
the activity of these antioxidant enzymes.  For example, HD patients were shown to have a significantly 
higher carotid artery intima media thickness (CIMT) compared with healthy controls, and the levels of 
SOD and GPX were negatively correlated with CIMT.
12
  Another study showed that the specific activity of 
SOD2 in Apoe
-/-
 mice exposed to second hand smoke was significantly decreased and mitochondria 
function was impaired.
20
  In another study, endothelial cells isolated from type 2 diabetes mice had a 
lower level of SOD2 expression compared with non-diabetic controls, which was associated with a higher 
amount of mtROS and impaired endothelial function.
18
   Together, these observations suggest that 
mitochondrial oxidative stress and damage in the advanced stages of atherosclerosis are due, at least in 
part, to the failure of antioxidant mechanisms.   The underlying mechanisms explaining the failure of 
mitochondrial antioxidant function in advanced disease stages are not completely understood.  Examples 
of hypotheses being explored in this area include peroxynitrite-mediated inactivation of MnSOD2
21
 and 
proteasome-mediated degradation of certain antioxidant enzymes.
18
    
 Experimental models have been used to test the concept that antioxidant enzyme disruption can 





mice have accelerated atherosclerosis, mtDNA damage, and accumulation of 3-nitrosylated proteins, 





cigarette smoke, which enhances the degree of oxidative stress.
20
  Moreover, Apoe
-/-
 mice with a targeted 
deletion of mitochondrial-localized GPX1 had accelerated atherosclerosis compared with Gpx1
+/+
 control 
mice, but only after long-term WD feeding
22
 or under diabetic conditions.
23
  Our group has addressed this 
issue by quelling endogenous mtROS in macrophages in the setting of atherosclerosis.  We used a 
macrophage-targeted transgenic catalase (mCAT) model in which the presence of catalase in the 
mitochondria matrix degrades H2O2.  Macrophages in mCAT lesions were protected from mtDNA 




   
 The general role of ROS in atherosclerosis represents a highly controversial area.
15, 25-27
  One 
possible explanation is the differential roles of various ROS-generating systems in lesional cells.  For 
example, mouse models of atherosclerosis with deletion of the NADPH oxidase (NOX) component P47
27
 
or with overexpression of catalase,
26, 27
  which reduces cytosolic H2O2, had less atherosclerosis.   
However, no athero-protective effect was found in a model with overexpression of Cu/Zn-SOD (Sod1), a 




   The explanation may lie in divergent intracellular signaling 
pathways triggered by ROS from specific cellular compartments.  For example, one study showed 
cytosolic SOD1 can suppress smooth muscle cell (SMC) proliferation through the inhibition of mitogenic 
ERK/P38 MAPK pathways.  In contrast, mitochondrial SOD2 suppresses SMC proliferation by inhibiting 
JAK2/STAT signaling.
28
   Another study demonstrated that angiotensin II activated the kinases MAPK, 
JNK and ERK5 through NOX-derived ROS, while ET-1 activated these enzymes through mtROS.
4
   
Therefore, in order to guide the development of antioxidant therapy, we need a more thorough 
understanding of the differential roles of the various ROS-generating systems in cells in the specific 
disease settings.      
 
 Autophagy (mitophagy) dysfunction.  Macroautophagy (autophagy) is a cellular process that 
delivers cytoplasmic contents to lysosomes for degradation and recycling.  Because normal mitochondrial 
function is critical for cell survival, cells develop a defense mechanism against aberrant or damaged 
mitochondria.   This machinery involves selective recognition, sequestration, and subsequent clearance 
of damaged mitochondria using the common machinery of macroautophagy.  This process has been 
called mitochondria autophagy, or mitophagy.
29





excessive mtROS, because mtROS is known to accumulate in damaged mitochondria.  Interestingly, 
mtROS itself regulates mitophagy.  Excessive mtROS can lead to mitochondrial depolarization, and the 
loss of ΔΨ can trigger E3 ubiquitin ligase-mediated Parkin activation.  Parkin then ubiquitinates 
mitochondrial proteins, and these ubiquitinated proteins serve as a signal for mitophagy.
30, 31
  Parkin itself 
can be modified by oxidative/nitrosative stress but then inactivated under excessive oxidative stress 
conditions,
32, 33
 which can lead to the failure of mitophagy.  ROS can also directly regulate 
autophagosomes formation.  ATG4, an essential component of autophagy, is subject to oxidation and 
subsequent inactivation by excessive ROS, which can then lead to dysregulation of mitophagy.
31
   
 An interesting hypothesis is that basal mitophagy is athero-protective by disposing of damaged 
mitochondria and this process may go awry in advanced atherosclerosis.  Defective mitophagy would 
then promote mitochondrial dysfunction and cell apoptosis, which is a process that can lead to the 
formation of necrotic cores and unstable plaques.  Two recent mouse atherosclerosis studies studied the 
effect of deletion of the essential autophagy protein ATG5 in macrophages.
34, 35
  In one study, the primary 
observation was larger lesion area associated with enhanced inflammasome activation.  Given links 
between mtROS and inflammasome activation,
36, 37
 the authors proposed that the potential underlying 
mechanism was related to a defect in mitophagy, and although mtROS was not measured, there was an 
increase in lesional protein oxidation and superoxide.  The other study found an increase in necrotic 
lesions in the ATG5-deficient mice, which was associated with an increase in lesional NOX activity and 
ROS.  Here again mtROS was not assayed, but ROS from NOX and other sources has been shown in 
other models to induce mtROS from mitochondria in a process called ROS-induced ROS release 
(RIRR).
38
  Although mtROS was not specifically assayed, we found that the mitochondria in macrophages 
of the ATG5-deficient lesions demonstrated loss of normal cristae morphology and were swollen 
(unpublished data).  Thus, it is possible that production of mtROS could result from cytosolic ROS 
accumulation,
39, 40
 and without mitophagy, mtROS-damaged mitochondria accumulate and activate 
mitochondrial cell death pathways.
38, 41
 This hypothesis is supported by data from our group (unpublished) 
and others that mtROS is higher in ATG5-deficient vs. wild-type macrophages
42
  and that damaged 





 A recent study used a genetic model with deletion of LOX-1, the receptor that mediates oxLDL-
induced autophagy.  They showed that human umbilical vein endothelial cells (HUVECs) without LOX-1 
had diminished autophagy induction, increased mtROS, and damaged mtDNA-induced TLR9 activation 




 mice had diminished autophagy, increased 
mtROS-induced mtDNA damage, more potent activation of TLR9, and increased lesional macrophage 
infiltration.  These data raise the possibility that mtROS-induced mtDNA damage that escapes mitophagy 
can induce a potent TLR9 activation in atherosclerosis.
43
  In summary, it is possible that a failure of 
mitophagy in advanced atherosclerosis promotes excessive mtROS and the accumulation of damaged 
mitochondria, which in turn could trigger inflammatory responses and cell death.  However, this 
hypothesis is based on models in which overall autophagy is disabled.  Thus, more specific models in 
which mitophagy is specifically inactivated or enhanced are needed to test the role of mitophagy in 
atherosclerosis.    
 
 Mitochondrial fission and fusion.  The mitochondrial dynamic processes of fission and fusion 
influence and integrate with multiple physiologic and pathophysiologic processes, including mitosis, 
mitochondria metabolism, mitochondrial quality control (mitophagy), mtROS, and cell death.
44-46
  
Diseases such as pulmonary arterial hypertension, arterial restenosis, hypertension, Parkinson’s disease, 
and obesity and diabetes have been associated with abnormalities in mitochondrial dynamics.
47-49
  
Mitochondrial fission and fusion are regulated by several different GTPases.  Mitofusin 1 (MFN1) and 
mitofusin 2 (MFN2) regulate outer membrane fusion, whereas optic atrophy protein 1 (OPA1) mediates 
inner membrane fusion.  Mitochondrial fission is activated by a cytosolic molecule called dynamin-related 
protein 1 (DRP1) and its docking protein fission 1 (FIS1) and mitochondria fission factor (MFF).  It is 
known that under stress conditions such as hyperglycemia, ischemia reperfusion, neurodegeneration, 
and aging, mitochondria usually undergo hyperfission.  Hyperfission has been shown to induce excessive 
mtROS in vascular smooth muscle cells (VSMC), cardiomyocytes, renal cells, fibroblast, and neurons.
44-46
  
MFN2 deficiency and DRP1 activation have been linked to smooth muscle cell (SMC) hyperproliferation in 
pulmonary artery hypertension.
50, 51
  In atherosclerosis, data suggest that mitochondria dynamic changes 







 mice artery during the development of atherosclerosis.
52
  Given that mtROS increases with lesion 
progression, this observation suggests the theoretical possibility that a decrease in MFN2 may 
progressively shift the mitochondria morphology toward hyperfission, which in turn may contribute to 
excessive mtROS production.  Consistent with this idea, a study in rabbit reported that overexpression of 
MFN2 was associated with reduced atherosclerosis.
53
  Interestingly, diabetic venous endothelial cells 
were shown to have increased mitochondrial fission and a higher level of the mitochondrial fission protein 
Fis1, which could contribute to mtROS overproduction and enhanced susceptibility to atherosclerosis.
54
  
While these studies hint at some interesting associations between mitochondrial dynamics and 
atherosclerosis, more precise in vivo models and more in-depth mechanist studies are needed to address 
the functional significance of mitochondria fission and fusion in atherosclerosis.   
 
Dysregulation of UCP2.  Uncoupling protein 2 (UCP2) is a mitochondria inner membrane protein 
that decreases mtROS production and is the dominant form of UCP that is expressed in vascular cells.   
UCP2 promoter polymorphisms in humans are associated with multiple pathological conditions, including 
obesity, diabetes, and atherosclerosis.
55-58





 mice have larger and more macrophage-rich atherosclerotic 




   The increase in atherosclerosis is associated 
with increased mtROS production.  Interestingly, the compensatory enhancement of antioxidant activity, 
including SOD2 and GPX1, that normally occurs in early lesions is blunted in the setting of UCP2 
deficiency.  These data suggest that UCP2 is up-regulated in response to an atherogenic diet and is 
required to maintain normal antioxidant activity in the mitochondria of vascular cells.  Mechanistically, 
UCP2 can suppress mtROS production, maintain normal endothelial function (eNOS release), promote 
vascular relaxation, decrease NF-κB activation, and inhibit the expression of the pro-inflammatory 
adhesion molecule VCAM-1 expression in endothelial cells.
60, 61
   Overexpression of UCP2 in THP-1 
monocytes quenches steady-state ROS production, which would be expected to decrease 
transendothelial migration of monocytes.
62
  Taken together, these data suggest that UCP2 is a part of the 
protective compensatory response that maintains the adaptive activation of SOD2 and GPX1 and their 









up-regulated and activated during early atherosclerosis and how it is affected by atherosclerosis 
progression are not known.  Thus, further causation studies are required to test the hypothesis that UCP2 
dysfunction contributes to the failure of antioxidant capability and leads to mtROS overproduction in 
























Consequences of excessive mtROS 
 Overproduction of mtROS may increase inflammation in atherosclerosis.  mtROS has been linked 
to the activation of inflammatory pathways involving NF-κB, TLR9, and the inflammasome.  Our group 
reported that mtROS can activate the IKK-NF-κB pathway and thereby enhance the induction of the 
chemokine CCL2 in LPS-treated macrophages.  In atherosclerotic lesions, suppressing mtROS in 
macrophages reduces inflammatory cytokine expression, including TNF-α and iNOS.
24
  Similar to 
bacterial DNA, mtDNA contains inflammation-inducing unmethylated CpG motifs .  In ischemia-
reperfusion, shock, tissue injury settings, and systemic inflammatory syndromes, damaged mtDNA is 
sensed by TLR9 and thereby amplifies the inflammatory response. 
64, 65
  Blocking mtROS-induced mtDNA 
leakage has been shown to suppress TLR9 activation in HUVECs in vitro and in Ldlr
-/-
 lesions.  Activation 
of TLR9 signaling correlates with an increased macrophages in lesions, suggesting a pro-inflammatory 
role of mtDNA in atherosclerosis.
43
  Furthermore, human and animal studies have provided evidence 
supporting the causative role of the NLRP3-IL-1β inflammasome activation in atherosclerosis,
66-68
  and 
mtROS and oxidative mtDNA damage has been linked to inflammasome activation under multiple 
pathological conditions.
36, 37
  The exact role of a mtROS-inflammasome axis in atherosclerosis requires 
further investigation using tools that specifically manipulate and measure these processes.   
 
mtROS and mtDNA damage in atherosclerosis.  mtDNA contains 13 genes encoding essential 
proteins involved in oxidative phosphorylation (OXPHOS), 12S and 16S ribosomal RNAs, and 22 transfer 
RNAs.  As mentioned previously in this review, mtDNA is more vulnerable to ROS-induced damage than 
nuclear DNA.
9
  Signs of mtDNA damage, including mtDNA mutations and deletions, and the 
aforementioned 5-kb mtDNA deletion have been identified in atherosclerotic lesions and are correlated 
with the extent of atherosclerosis.  Additionally, mtDNA mutations in the MT-RNR1, MT-TL1, MT-ND2, 
MT-ND5 and MT-CYB genes are associated with atherosclerosis in human plaques.
69
  Diabetes is one of 
the major risk factors for atherosclerosis, and there is a report that diabetic atherogenesis is associated 
with decreased mtDNA copy number.
70
   
 A recent study examined Apoe
-/-
 mice that were haploinsufficient for the protein kinase ATM, 





of metabolic syndrome and accelerated atherosclerosis, with increased frequency of the 5-kb mtDNA 
deletion and reduced oxidative phosphorylation.  These changes were abrogated by transplantation of 
WT bone marrow into to the ATM-deficient mice,
71
  indicating the involvement of myeloid-derived cells.  
To further clarify the role of mtDNA in atherosclerosis, the same group targeted DNA polymerase gamma 





mice accumulated somatic point mutations in mtDNA and accelerated 
atherosclerosis.
72





lesions had enhanced mtDNA damage, reduced levels of ETC complex I, II and IV, and dysfunction of 
mitochondrial OXPHOS.  To probe the cellular mechanisms, the investigators treated HUVECs and 
human aortic smooth muscle cells (HASMCs) with H2O2 and ONOO
−
 and found mtDNA deletions, 
decreased mtDNA-encoded mRNA and proteins, reduced ATP levels, and loss of ΔΨ.
73
  These data 
support the notion that somatic mtDNA mutations are sufficient to cause atherosclerosis progression.   
 
Lipid peroxidation and abnormal protein modification.  mtROS also leads to abnormal 
mitochondrial protein modification, including cysteine oxidation, cysteine nitrosylation and tyrosine 
nitration, and lipid peroxidation followed by degradation.  O2•
- 
interacts with NO to form OONO
-
, a highly 
reactive species that can nitrate tyrosine residues and nitrosylate serine residues.  •HO derived from H2O2 
through the Fenton reaction leads to mtDNA oxidative damage and protein oxidation.  These protein 
modifications can result in detrimental consequences, such as alteration of protein function, activation of 
immune and inflammatory responses, and activation of cell death pathways.
16, 74
  Oxidatively modified 
proteins and lipoproteins, including oxidized LDL, lipid peroxidation products, and nitrated tyrosines, have 
been identified in patients with coronary artery disease and in atherosclerotic animal models.
15, 75, 76
  
Mitochondrial antioxidant enzymes and ETC complexes could be potential targets of such abnormal 
protein modifications.  For example, tyrosine nitration of MnSOD2 by OONO
-
 causes inactivation of 
MnSOD2, which may contribute to the overproduction of mtROS in vascular cells. 
21, 77
   Another study 
using rat pulmonary microvascular endothelial cells demonstrated that NO and mitochondrial derived O2•
- 
altered mitochondrial function through tyrosine nitration of a mitochondrial protein called NDUFB8, which 
then triggered RIP1-mediated cell necrosis.
78





progresses, which may not only be a marker of mtROS but might contribute to pathophysiology.
16
  In 
summary, mtROS-induced modification of mitochondrial proteins and lipids could very well contribute to 




 An increasing numbers of studies have suggested an association between mtROS and 
atherosclerosis, and a few of these have begun to address the critical issue of causation.  Moreover, 
mechanistic studies have explored how a healthy level of mtROS is maintained in physiology; how it may 
go awry in pathophysiology, including advanced atherosclerosis; and how excessive mtROS promotes 
disease progression (Figure I).  Further understanding of these issues in the area of advanced 
atherosclerosis progression may provide new and more specific therapeutics.  This more targeted 
approach may overcome some of the inconsistencies that have plagued the general field of anti-oxidant 

































Figure I:  Regulation of healthy level and excessive mtROS.   
A, Under physiological conditions, mtROS is generated as a byproduct of electron transport and 
quenched by the mitochondrial antioxidant enzymes (MnSOD and GPX).  Moreover, mtROS production is 
tempered by uncoupling protein  2 (UCP2).  In the course of normal mitochondrial physiology, sporadic 
episodes of mitochondrial dysfunction are handled by a process involving mitochondrial fission and 
mitophagy.  Fission is promoted by the proteins DRP1 and FIS1, and the converse process of fusion is 
promoted by MFN1/2 and OPA1.  PINK1 and Parkin mediate the ubiquitination and recognition of 
damaged mitochondria by the mitophagy complex, which is depicted by the double membrane structure.  
B, Under pathophysiologic conditions, excess mtROS,  especially the highly reactive molecules •HO and 
OONO
-
, can result from (1) inactivation or degradation of MnSOD; (2) inactivation of Gpx; (3) dysfunction 
of UCP2 ; (4) dysregulation of mitochondrial fission/fusion dynamics; (5) or inactivation mitophagy lead to 
mitophagy deficiency.  Excessive mtROS can damage electron complex complexes and reduce ATP 
generation; oxidatively damage mtDNA, leading to inflammasome activation; trigger cytochrome C (CytoC) 
release and apoptosis; and open the mitochondria permeable transition pore (mPTP) to cause cell 























Macrophage Mitochondrial Oxidative Stress Promotes Atherosclerosis and Nuclear Factor-κB-Mediated 










* This chapter is from the article “Macrophage Mitochondrial Oxidative Stress Promotes Atherosclerosis 
and Nuclear Factor-κB-Mediated Inflammation in Macrophages”.  Circ Res. 2014 Jan 31;114(3):421-33, 






Oxidative phosphorylation in the mitochondria produces limited, physiologic levels of superoxide, 
most of which is converted to hydrogen peroxide by superoxide dismutase (SOD).
79
  While this process is 
adaptive under normal conditions, excessive mitochondrial oxidative stress (mitoOS) has been correlated 
with a number of diseases, including atherosclerotic vascular disease in humans.
80, 81
  However, definitive 
evidence of causation and cell-specific pro-atherogenic mechanisms of mitoOS require further 
investigation.
82, 83
  For example, while several important studies demonstrated that genetic targeting of 
Mn-SOD or uncoupling protein-2 increases mitoOS and worsens atherosclerosis,
15, 84
 the role of 
endogenous mitoOS is not addressed by this experimental strategy.  Another elegant study showed that 
endothelial-targeted overexpression of thioredoxin 2, an anti-oxidant enzyme that has been identified in 
mitochondria, increased total anti-oxidant activity, lowered ROS, promoted NO formation, and improved 
endothelial function.
81
  When crossed onto the Apoe
-/-
 background, thoracic aortic rings showed improved 
relaxation, and atherosclerotic lesion size was decreased.  Whether the atherosclerosis endpoint was 
mechanistically related to lesional endothelial mitoOS, the aortic ring data, or other possible mechanisms 
remains to be determined in this model.  
 The high level of interest in this topic, the human relevance, and the potential therapeutic 
implications prompted us to explore causation and mechanism with a focus on the key inflammatory cell 
type in atherosclerosis, the macrophage.  For this purpose, we used a recently described model, the 
mitochondrial catalase (mCAT) transgenic mouse, that decreases mitoOS in vivo.
5
  Normally, glutathione 
perioxidase is the endogenous mitochondrial enzyme that catalyzes the reduction of H2O2 and prevents 
its conversion into the most detrimental ROS hydroxyl nitrites.  Catalase can carry out this role in 
peroxisomes, where it is exclusively located.  The mCAT transgenic mouse expresses human catalase 
with a mitochondrial matrix-targeting motif, which quenches mitoOS and protects against mitoOS-induced 
damage.  To focus on myeloid-derived cells in atherosclerosis, we used two strategies:  transplantation of 
mCAT transgenic bone marrow cells into atheroprone Ldlr
-/-
 mice and crossing Ldlr
-/-
 mice with an 
mCAT
fl/-
LysMCre model that expresses mCAT only in lysozyme M-expressing cells, notably differentiated 
macrophages.  Both models demonstrated evidence of decreased mitoOS in lesional macrophages, 





mechanistic studies suggest that macrophage mitoOS promotes monocyte chemotactic protein-1 (MCP-1) 
























Animals and Diets 
C57BL/6J (000664) and Ldlr
-/-
 (002381) mice on the C57BL/6J background were purchased from Jackson 
Laboratory.  mCAT transgenic and floxed mice were generated as described previously 
5, 85
 and were 
backcrossed >10 times onto the C57BL/6J background.  For the atherosclerosis study, mCAT transgenic 
and age/gender-matched littermates were used as donors.  Ldlr
-/-
 male mice, at 14 weeks of age and 6 
weeks after the bone marrow transplant, were placed on a Western-type diet (TD88137; Harlan Teklad) 
for the indicated periods of time.    
 
Atherosclerotic Lesion Analysis  
For morphometric lesion analysis, sections were stained with Harris’ hematoxylin and eosin. The total 
lesion area and necrotic area were quantified as previously described.
86
  For immunostaining, specimens 
were immersed in OCT and 6-µm sections were prepared and placed on glass slides.  The sections were 
fixed and permeabilized with ice-cold acetone for 10 min.  Paraffin-embedded specimens were sectioned, 
de-paraffinized with xylene, and rehydrated in decreasing concentrations of ethanol.  Sections were then 
incubated overnight at 4C with anti-Mac-3 (BD Clone M3/84, 1:200), anti-8-OHdG (EMD Millipore, 
AB5830, 1:200), anti-NF-κB P65 p-S536 (Cell Signaling, 3033, 1:40), FITC-labeled smooth muscle cell 
-actin antibody (FITC-labeled, clone 1A4, Sigma-Aldrich, 1:1000), or anti-CD11c (PE labeled, clone 
HL3, BD Biosciences, 1:200) antibody.  The sections were then incubated with biotinylated anti-rat, anti-
goat IgG, or anti-rabbit secondary antibody (Vector) and then streptavidin-conjugated Alexa 488- or Alexa 
594-labeled antibody (Life Technology).  Sections were counter-stained with DAPI to identify nuclei 
before mounting.  
 
Measurement of 8-OHdG in Lesional and Cultured Macrophages  
Evidence of mitoOS in lesional macrophages was obtained by assaying oxidative damage of non-nuclear 
(mitochondrial) DNA.  Specifically, cryo-sections were stained sequentially with anti-8-





(Vector ABC Kit), Alexa 488- and 594-labeled streptavidin, and 4',6-diamidino-2-phenylindole (DAPI), 
which was used to measure the total number of cells and to identify nuclei.   Sections were then imaged 
by confocal microscopy (Nikon A1 Confocal with -100X oil objective at -0.10-μm thickness).  Data were 
quantified as both the percentage of total Mac3+ cells and the total number of Mac3+ cells showing 8-
OHdG staining that did not overlap with DAPI, i.e., as an indicator of exposure of mitochondrial DNA to 
oxidative stress.  To assay mitochondrial 8-OHdG in cultured macrophages, sections were fixed and 
permeabilized with pre-chilled acetone on ice for 10 min, stained with anti-8-OHdG and anti-ATP 
synthase 5α (Abcam ab110273 1:200) primary antibodies at 4°C overnight, followed by anti-goat-
Alexa488 and anti-mouse-Alexa647 secondary antibodies.  The sections were then counter-stained with 
DAPI and visualized by confocal microscopy as above.   
 
Measurement of Mitochondrial and Cytosolic ROS in Cultured Macrophages 
Peritoneal macrophages from adult female C57BL/6J mice and mCAT transgenic mice were harvested 3 
days after i.p. injection of concanavalin A or four days after i.p. injection of methyl-BSA (mBSA) in mice 
previously immunized with mBSA.
87
  All macrophages were grown in full medium containing Dulbecco's 
Modified Eagle Medium (DMEM; 25 mM glucose, phenol-red free), 10% fetal bovine serum (FBS), 20% L-
cell conditioned medium, and 1% penicillin/streptomycin/ glutamine solution (GIBCO) on non-tissue 
culture coated plates.  The medium was replaced every 24 h until the cells reached 90% confluence.  On 
the day of the experiment, the cells were pre-incubated with 5 µM of the mitochondrial superoxide 
indicator MitoSOX at 37°C for 30 min.  The cells were then rinsed in warm culture medium, and 
treatments as described in the figure legends were started 6 h later.  At the end of incubation period, cells 
were dissociated from the petri dish and subjected to flow cytometric analysis (BD Canto II) using the 
Phycoerythrin (PE) channel.  Data were quantified as fold change of medium fluorescent intensity (MFI) 
compared with baseline.   For live cell imaging, cells were stained with Mitotracker Green (100 nM) for 15 
min, followed by three washes with warm medium.  The cells were then imaged immediately at room 
temperature using confocal microscopy.  For measuring cytosolic ROS, cells were incubated with 2.5 µM 






Monocyte Infiltration Experiment 
To track newly recruited monocytes in atherosclerotic lesions, the Ly6c
hi
 subset of monocytes was 
labeled with fluorescent beads as described previously.
88
  Briefly, 96 h before the end of study, the mice 
were injected i.v. with 250 μl clodronate-containing liposomes 
(http://clodronateliposomes.org/ashwindigital.asp?docid=26) to deplete monocytes.  After 48 h, the mice 
were injected with 250 μl of a 1:4 dilution of 1 μm Fluoresbrite Plain YG microspheres (Polysciences).  
After another 48 h, the mice were euthanized, and peripheral blood samples were analyzed by FACS to 
quantify the efficiency of bead labeling of Ly6c
hi
 monocytes.  The heart and aortic tissues were processed 
as described above.  The newly recruited bead-labeled monocytes in atherosclerotic lesions were 
visualized by fluorescence microscopy and quantified using Image J. 
 
Reagents 
Falcon tissue culture plastic was purchased from Fisher Scientific.  Tissue culture media, cell culture 
reagents, and heat-inactivated fetal bovine serum (FBS) were from GIBCO.  Lipopolysaccharide (LPS) 
and concanavalin A were obtained from Sigma.  All organic solvents were from Fischer Scientific.  
MitoSOX, MitoTracker Green (MTG), CellROX Deep Red, and streptavidin-conjugated Alexa 488/594 
were obtained from Life Technology.  The insulin ELISA kit was from Millipore.  Antibodies were 
purchased from the following sources:  Cell Signaling Technology for p-NF-κB(S536), NF-κB, P-IKKα/β 
(T177), IKKβ , P38-MAPK, P-P38-MAPK, P-JNK(T183/Y185); BD Biosciences for CD45-APC, Gr-1-
PerCP, CD115-APC Cy5, Mac-3 antibody and biotinylated anti-rat IgG; Abcam for mouse monoclonal 
antibody to β-actin and catalase; R&D for ICAM-1 (AF720) and VCAM-1 (AF643); and Jackson 
ImmunoResearch for horseradish peroxidase-conjugated goat anti-rabbit IgG, donkey anti-mouse IgG 
secondary antibodies.   Lp(a) and oxLDL were purchased from biomedical technologies.  mmLDL was the 
gift from Dr. Yuri Miller at UCSD.   
 







 mice were lethally irradiated using an X-ray source (Precision X-RAD 320 
Biological Irradiator) at a dose of 1000 rad 4–6 h before transplantation.  Bone marrow cells were 
collected from the femurs and tibias of donor wild-type and mCAT transgenic mice by flushing with sterile 
medium as described previously.
89
  All animal procedures used in this study followed Columbia 
University’s institutional guidelines.    
 
Immunoblot 
Cells were lysed in a buffer containing 2x Laemmli sample buffer (Bio-Rad) plus 50 mM DTT and boiled at 
100ºC for 5 min.  Aliquots of lysate protein (100 µg) were separated on 4-20% gradient SDS-PAGE gels 
(Invitrogen) and electrotransferred to 0.45-µm nitrocellulose membranes using a Bio-Rad mini-transfer 
tank.  Membranes were incubated at 4C with primary antibodies overnight, and the protein bands were 
detected with horseradish peroxidase-conjugated secondary antibodies and Supersignal West Pico-
enhanced chemiluminescent solution (Pierce).  Membranes were stripped with Restore Western Blot 
Stripping Buffer (Pierce) for 15 min at room temperature before being immunoblotted with antibodies 
against housekeeping proteins, which were used as loading controls.  Image J software was used for 
quantification of densitometric ratio of protein of interest loading control.   
 
Macrophage Transfection 
Mouse IKK (11103) and RelA (20012) plasmids were purchased from Addgene.  Individual plasmids (0.5 
µg) were mixed with 2 μl jetPEI macrophage transfection reagent (VWR, 103-01N) and incubated with 
1.5x10
5
 peritoneal macrophages in 24-well plates at 80-90% confluence.  After 40 h, the macrophages 
were treated with LPS or vehicle as indicated.  Transfection efficiency was assayed by immunoblot 
analysis of IKK and RelA from total cell lysate.     
Peripheral Blood Cell Profiling 
At each time point, ~ 40 µl tail veil blood was collected in a heparinized capillary tube (Fisher Scientific) 
from each mouse.  A 20-µl aliquot was used for hemocytometer analysis (Oxford scientific), and the rest 





at room temperature.  After adding PBS, the leukocytes were collected by centrifugation at 4°C and then 
incubated for 15 min with combinations of CD45-APC, CD115-APC-Cy5, and Gr-1-PerCP antibodies (BD 
Biosciences) in the dark at room temperature.  After washing with PBS, the cells were analyzed by FACS 
using FSC/SSC and CD45
+











 population as Ly6c
low




 as neutrophils.   
 
Plasma Glucose, Cholesterol and Triglyceride Measurements 
Fasting blood glucose levels were measured using ONETOUCH Ultra strips after 12 h of fasting.  Total 
plasma cholesterol, HDL-cholesterol, and triglyceride were measured using commercially available kits 
(Wako Pure Chemical Industries).  Pooled plasma from 3 mice were used to obtain FPLC lipoprotein 
profiles.  Profiles were obtained using FPLC gel filtration and a Superose 6 column (Amersham 
Pharmacia) at a flow rate of 0.2 ml/min, followed by cholesterol assays of the fractions.  
 
Laser Capture Microdissection and Quantitative PCR 
Serial OCT-embedded sections were fixed in xylene for 10 min and then air-dried for 5 min at room 
temperature.  Lesional RNA was captured by a PALM laser capture microdissection machine.  The 
collected samples were lysed in RLT buffer (Qiagen) and were immediately frozen on dry ice.  RNA was 
extracted using the RNeasy Micro Kit (Qiagen).  The purity of the RNA was measured by absorbance at 
260 and 280 nm using NanoDrop spectrophotometry (Thermo Scientific).  RNA with an A260/280 of >1.8 
was used for cDNA synthesis with M-MLV reverse transcriptase (Life Technology).  QPCR was performed 
in a 7500 Real-Time PCR system (Applied Biosystem) using SYBR green chemistry.  Mouse Tnfa, Mcp1, 
Actb (β-actin), Ccr7, Gapdh, Ntn1, Ccr5, Ccl5, Cxcl1, Cxcr1, Cx3cl1 and Inos primers were purchased 
from Qiagen.   
 
Statistics 
Values are given as means ± S.E.M. unless otherwise noted, with n number for each experiment listed in 





symbols.  Comparison of mean values between two groups was usually evaluated by a Student t-test.  
When the data did not fit a normal distribution, the Mann-Whitney U rank-sum test was used.  
Comparison of multiple mean values was evaluated by ANOVA.  Linear regression analysis was 























Oxidative DNA Damage Surrounding Mitochondria in Lesional Macrophages Correlates with 
Atherosclerosis Lesion Progression in Western Diet-Fed Ldlr
-/-
 Mice   
Oxidative damage to nuclear and mitochondrial DNA (mtDNA) can be assessed by immunostaining for 
nuclear and non-nuclear 8-OHdG, respectively.
90, 91
  Thus, a non-nuclear 8-OHdG immunostaining is 
observed when mitochondria are exposed to excessive oxidative stress, referred to here as "mitoOS."  To 
illustrate this assay, cultured macrophages were subjected to various treatments and then immunostained 
for 8-OHdG (green) and the mitochondrial marker ATP5α (red) (Figure 1.1A).  For some of the treatments, 
the cells were assayed by flow cytometry for mitoOS using MitoSOX and for general cellular reactive 
oxygen species (ROS) using CellROX.  Compared with vehicle control, H2O2 treatment, which causes 
general oxidative stress in cells, yielded a positive 8-OHdG signal, some of which overlapped with the 
mitochondrial marker (yellow staining in cytoplasm) and some of which was juxtaposed with DAPI (blue)-
stained nuclei.  Short-term treatment with phorbol myristate acetate (PMA) activates NADPH oxidase, not 
mitoOS, and we saw no 8-OHdG-mitochondrial co-localization despite robust activation of the CellROX 
signal.  As will be described in later sections, oxidized LDL (oxLDL) is an athero-relevant inducer of 
oxidative stress in macrophages, and we found that it also activates mitoOS, i.e., there is ample evidence 
of punctate yellow staining in the cytoplasm, indicative of 8-OHdG-mitochondrial co-localization.  
Lipopolysaccharide (LPS) also activates mitoOS (below), and here again 8-OHdG-mitochondrial co-
localization was seen.  These data provide validation for the use of non-nuclear 8-OHdG, which reflects 
mitochondrial DNA oxidative damage, as a marker of mitoOS.    
 We next assessed nuclear and mitochondrial oxidative DNA damage in atherosclerotic lesional 
macrophages in aortic root lesions from 8-wk Western diet (WD)-fed Ldlr
-/-
 mice.  Sections were 
immunostained with the macrophage marker anti-Mac3, the nuclear marker DAPI, and anti-8-OHdG, or 
the respective isotype-matched IgGs as negative controls, as illustrated by the images in Figure 1.1B.  
For quantification, lesional sections from multiple mice were viewed and quantified by confocal 
fluorescence microscopy to look for punctate 8-OHdG staining that was either cytoplasmic or nuclear, i.e., 
similar to the pattern of non-nuclear or nuclear 8-OHdG staining in culture macrophages, respectively.  





Increasing WD feeding for 12 and 16 wks, which is known to increase aortic root lesion area
92
 (data not 
shown), led to a progressive increase in both the percent and total number of macrophages showing this 
pattern (Figure 1.2B).  By comparison, the percent of macrophages with nuclear 8-OHdG staining showed 
similar levels at 8 and 12 wks of WD feeding and then an increase above that level at 16 wks, while the 
total number of nuclear 8-OHdG macrophages continuously increased as lesions progressed (Figure 
1.2C).  These data validate the use of the WD-fed Ldlr
-/-
 model to further study a known feature of human 
atherosclerotic lesions,
15
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Figure 1.1:  Oxidative damage of non-nuclear and nuclear DNA in cultured macrophages and aortic root 
lesional macrophages of WD-fed Ldlr
-/-
 mice.   
(A) Peritoneal macrophages were incubated with vehicle control or H2O2 (30 min), PMA (5 min), oxLDL (6 
h), or LPS (6 h).  The cells were then immunostained using antibodies against 8-OHdG and the 
mitochondrial marker ATP synthase 5α and viewed by fluorescence microscopy.  The 4
th
 columns of 
images are higher magnifications of the boxed areas in 3
rd
 column of images.  Bars, 5 μm for the first 3 
column of images and 1 μm for the fourth column.  Flow cytometric quantification of mitochondrial 
superoxide (mitoSOX) and total cellular ROS (CellROX) are shown in the graphs (*P<0.05; n = 3 set of 
macrophages in each group).  (B) A section from an aortic root lesions of a 8-wk WD-fed Ldlr
-/-
 mouse 
was subjected to immunofluorescence staining using anti-8-oxyhydrodioxy guanosine (8-OHdG), a 
marker of DNA oxidative damage (green).  Macrophages were stained using anti-Mac3 (red), and nuclei 
were stained with DAPI (blue).  Shown are representative images stained with anti-8-OHdG or anti-Mac3 
















































Figure 1.2 A 
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Figure 1.2:  Oxidative damage to mitochondrial DNA in lesional macrophages correlates with 
atherosclerosis progression in Ldlr
-/-
 mice.   
(A) Aortic root lesions of 8-wk WD-fed Ldlr
-/-
 mice were subjected to immunofluorescence staining using 
anti-8-oxyhydrodioxy guanosine (8-OHdG), a marker of DNA oxidative damage (green).  Macrophages 
were stained using anti-Mac3 (red), and nuclei were stained with DAPI (blue).  The upper row of images 
shows a representative lesional section at low magnification, with the intima outlined with the dotted line.  
Bar, 10 μm.  The two boxed areas in the fourth low-magnification image are shown at higher 
magnification in the lower two rows of images.  In the merged image, when the green 8-OHdG signal is 
nuclear, it retains its green fluorescence and is juxtaposed with the blue nuclei (arrowheads), whereas 
when it is non-nuclear, the green fluorescence "merges" with the red cytoplasmic fluorescence (Mac3) 
and appears as yellow dots (arrows).  Bar, 2.5 μm.  (B) Aortic root lesions from 8-, 12-, and 16-wk WD-fed 
Ldlr
-/-




 cells among all lesional 
Mac3
+




 cells per section; the number of 
mice examined for each of the three WD durations were 4, 5, and 5, respectively (*P<0.05 vs. 8-wk group; 
#
P<0.05 vs. 12-wk group; n = 4, 5, and 5 mice for 8-wk, 12-wk, and 16-wl lesions, respectively).   (C) 
Aortic root lesional macrophages from the indicated groups of mice (see Figure 1B) were stained for DAPI 
and 8-OHdG, and then the macrophages in which 8-OHdG staining overlapped with DAPI (nuclear 8-
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cells per section (bottom) (n = 4, 5, and 5 mice for 8-
wk, 12-wk, and 16-w, lesions, respectively; *P<0.05 vs. 8-wk group; 
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Suppression of MitoOS in Myeloid Cells Protects Against Atherosclerosis    
To test the functional importance of mitoOS in lesional myeloid-derived cells, we transplanted bone 
marrow from mCAT transgenic or littermate control mice into Ldlr
-/-
 recipients.  Six weeks after 
transplantation, the mice were placed on a high-fat Western-type diet (WD) for 8 weeks.  Bone marrow-
derived macrophages (BMDMs) from the mice showed expression of human catalase mRNA only in the 
mCAT group, and immunoblot assay of total catalase showed a higher level in the mCAT vs. control 
macrophages (Figure 2.1A).  Only macrophages from the mCAT mice showed co-localization of catalase 
with the mitochondrial marker ATP synthase 5α (ATP5α) (Figure 2.1B).  Using mRNA captured from 
aortic root lesions by laser-capture microdissection (LCM), we found that human catalase mRNA was 
expressed only in the mCAT group (Figure 2.1C), whereas lesional murine catalase mRNA did not differ 
significantly between the two groups (data not shown).   
 We next analyzed non-nuclear 8-OHdG in lesional macrophages and found suppression of this 
marker in the mCAT group (Figure 2.1D).  In contrast, nuclear 8-OHdG was similar between the two 
groups.  These data support both the usefulness of the non-nuclear 8-OHdG marker in lesions and the 
overall strategy of the experimental design.   Most importantly, aortic root lesion area was, on average, 
~2.5-fold lower in the mCAT group (Figure 2.1E).  The decrease in atherosclerosis in the mCAT group 
was maintained after 16 wks of WD feeding (Figure 2.2).  The two groups of mice had similar weights, 
fasting plasma glucose levels, and plasma lipids and lipoprotein concentrations after 8 wks of WD feeding 
(Figure 2.3).  As is usually the case with mouse models of atherosclerosis, the lesion area data showed a 
wide range of variability, and we took advantage of this spread to test whether there was a correlation 
between non-nuclear 8-OHdG and lesion area in the combined group of mice (Figure 2.1F).  This 
analysis revealed a strong positive correlation between these two parameters, whereas there was no 
correlation between nuclear 8-OHdG and lesion area.  Finally, we tested the effect of macrophage mCAT 
using a non-BMT model.  For this purpose, Ldlr
-/-
 mice were crossed with a cre-lox model that expresses 













 mice.  The 
two groups of mice did not differ with respect to body weight, plasma lipids, or fasting glucose (data not 





from the LysMCre mice contained macrophages having lower levels of non-nuclear but not nuclear 8-
OHdG, and the lesions were smaller in a manner that correlated strongly with lesional macrophage non-
nuclear 8-OHdG (Figure 2.3).  In summary, expression of mitochondria-targeted catalase in myeloid cells 
lowers a marker of mitoOS in lesional macrophages and, in direct proportion to this parameter, decreases 




















































































































Figure 2.1:  Suppression of myeloid cell mitoOS protects against early atherogenesis in mCAT transgenic 
 Ldlr
-/-
 chimeric mice.   
mCAT transgenic (mCAT)  Ldlr
-/-
 and littermate control  Ldlr-/- chimeric mice were fed the WD for 8 
wks, and bone marrow-derived macrophages (BMDMs) and aortic root lesions were analyzed as below.  
(A) Relative expression of human catalase (Hucat) mRNA and protein in BMDMs (n = 4 control vs. 5 
mCAT mice; *P<0.05).  (B) Representative confocal microscopic images of catalase and ATP5α 
(mitochondria marker) in BMDMs.  The 4
th
 column of images is a higher magnification of the boxed 
sections in the 3
rd
 column of images.  Bars, 5 μm for the first 3 column of images and 2 μm for the last 
column.  (C) Relative human catalase mRNA in aortic root lesions by laser capture microscopy (LCM).  (D) 
Quantification of nuclear and non-nuclear 8-OHdG-positive Mac3+ macrophages as a percentage of total 
Mac3+ cells (two graphs on the left) and per section (two graphs on the right) in aortic root lesions (n = 10 
control vs. 9 mCAT mice; *P<0.05; N.S., non-significant).  (E) Representative H&E-stained aortic root 
lesions, with the intima marked by dotted lines, and total lesion area quantification (n = 19 mice/group; 


































































Figure 2.2:  The athero-protective effect of myeloid mCAT persists after 16 wks of WD feeding.  
(A) Representative H&E-stained aortic root lesions and total lesion area quantification in control  Ldlr
-/-
 
and mCAT  Ldlr
-/- 
mice that were fed the WD for 16 wks (n = 9 control vs. 11 mCAT mice; *P<0.05).  




 macrophages as a 
percentage of total Mac3
+
 cells (upper two graphs) in the aortic root lesions of the two groups of mice (n = 
9 control vs. 11 mCAT mice; *P<0.05; N.S., non-significant).  (C) Graph of nuclear and non-nuclear 8-



































Figure 2.3:  Metabolic parameters of 8-wk WD-fed control  Ldlr
-/-
 and mCAT  Ldlr
-/-
 mice.   
Plasma lipids, lipoproteins, fasting glucose, body weight, and FPLC profile of lipoprotein-cholesterol were 












Figure 2.4 A 
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Figure 2.4:  Suppression of mitoOS in lysozyme M-expressing cells protects against early atherogenesis 
in Ldlr
-/-











 mice were fed the WD for 8 wks, and aortic root 





macrophages as a percentage of total Mac3
+
 cells (upper two graphs) and per section (lower two graphs) 
in the aortic root lesions of the two groups of mice (n = 14 Cre- vs. 10 Cre+ mice; *P<0.05; N.S., non-
significant).  (B) Representative images of nuclear and non-nuclear 8-OHdG staining in lesional 
macrophages in the two groups of mice using the same staining procedure as in Figure 1.  The first two 
rows of images are low-magnification, with the intima outlined by the dotted line; the 3
rd
 row image is a 
higher magnification of the boxed areas in the 2
nd
 row of images.  As in Figure 1A, nuclear 8-OHdG is 
depicted by arrowheads and non-nuclear 8-OHdG by the arrow.  Bars, 10 μm for the first 2 rows of 
images and 1 μm for the third row.  (C) Representative images, with outlined intima, and quantification of 
total lesion area in the two groups of mice (n = 14 Cre- vs. 10 Cre+ mice; *P<0.05).  Bar, 40 μm; * P < 














Suppression of MitoOS in Myeloid Cells Decreases Monocyte Infiltration, Inflammation, and RelA NF-κB 
Activation in Atherosclerotic Lesions 
To explore the mechanisms of how suppression of myeloid cell-derived mitoOS decreases 
atherosclerosis, we analyzed the cells and extracellular matrix of aortic root lesions from 8-wk WD-fed 
mCAT  Ldlr
-/-
 and wild-type littermate  Ldlr
-/-
 chimeric mice.  At this stage of atherosclerosis, most of 
the variability in aortic root lesion area among individual mice can be explained by the number of lesional 
cells (Figure 3.1A), whereas the extracellular matrix area was very small and not noticeably different 
between the two groups of lesions (data not shown).  In particular, the mCAT-positive lesions had smaller 
numbers of total cells, Mac3+ cells (macrophages), and CD11c+ cells (cells having properties of dendritic 
cells
94
).  In contrast, the numbers of lesional smooth muscle cells and CD3+ T cells were similar between 
the two groups of mice (Figure 3.1B).  
 The decrease in myeloid-derived cells in the mCAT-positive lesions could, in theory, be due to 
increased apoptosis, followed by rapid efferocytosis,
95
 or to decreased proliferation.  However, TUNEL-
positive staining as a marker of apoptosis was identical in these early lesions of the two groups(Figure 
3.2A).  The number of Ki67-positive lesional macrophages as a marker of macrophage proliferation was 
similar between the two groups of mice, and cultured macrophages from mCAT-positive and control mice 
had similar proliferation rates (Online Figure 3.2B).  Another mechanism could be decreased retention or 
increased egress of lesional macrophages, but the mRNA level for a key molecule that mediates retention, 
netrin-1,
96
 was not decreased in the mCAT lesions, and the mRNA level for the egress mediator CCR7
97
 
was similar between the two groups (Figure 3.2C).  Interestingly, there was a marked increase in netirn-1, 
which might represent a compensatory response that is subservient to the dominant mechanism of 
lesional myeloid cell decrease described below.    
 We next turned our attention to the hypothesis that suppression of mitoOS by mCAT decreased 
blood monocyte infiltration into lesions, with an emphasis on the Ly6c
hi
 subpopulation of monocytes, 
which contributes to lesion progression.
98
  Monocyte infiltration into lesions involves both chemokine-
mediated monocyte migration (chemokinesis) and endothelial cell monocyte-adhesion molecules.  To test 
whether chemokinesis was lower in mCAT mice, mCAT transgenic  Ldlr
-/-
 and wild-type littermate  
Ldlr
-/-










  Lesions were than analyzed for labeled cells 48 h later (Figure 3.3A).  Total lesion 
area significantly correlated with the number of beads (Figure 3.3A, left graph), consistent with the 
important role of monocyte chemokinesis in lesion progression.
98
  Most importantly, mCAT-positive 
lesions had a significantly lower number of bead-labeled cells, suggesting decreased chemokinesis 
(Figure 3.3A, right graph).  In consideration of the former mechanism, we assayed the expression levels 
of intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) on 
lesional endothelium, but the levels were not decreased in the lesions of mCAT mice (Figure 3.3B).  In 
theory, this finding could be explained by a decrease in peripheral monocyte count,
99
 but the number of 




) were similar between the two groups of 
mice (Figure 3.3C). 
 MCP-1 is a major monocyte chemokine in atherosclerosis,
100, 101
 and our group recently showed 
that immunoneutralization of MCP-1 in WD-fed Ldlr
-/-
 mice decreased the entry of monocytes into 
lesions
94
.  In this context, we interrogated lesions for Mcp1 mRNA and found a marked decrease in the 
lesions of mCAT mice (Figure 4A, left graph).  Note that plasma MCP-1 and lesional mRNAs for other 
chemokines and their receptors, including Ccl5, Cx3cl1, Cxcl1, Ccr5, Cx3cr1, were not different between 
the two groups of mice (Figure 4B).  MCP-1 is induced in response to activation of inflammatory pathways 
in macrophages, and so we reasoned that mCAT-mediated suppression of Mcp1 might be part of a larger 
program of inflammation suppression.  Consistent with this idea, the mRNAs of two other inflammatory 
markers, Tnfa and Inos, were also markedly reduced in the lesions of the mCAT group (Figure 4A, middle 
and right graph). 
 A key inflammatory pathway involves the transcription factor RelA (p65) of the NF-κB pathway.  
To assess whether this pathway was affected by mCAT, we assayed a marker of pathway activation, 
namely, nuclear localization of Ser536-phosphorylated RelA.
102, 103
  Analysis of macrophage-rich areas of 
lesions for co-localization of DAPI and p-RelA showed a clear decrease in nuclear RelA in the lesions of 
mCAT mice (Figure 4D).  In contrast, SMC-rich areas and the endothelium showed no difference in 
nuclear p-RelA between the two groups.  These combined data are consistent with the idea that mCAT 

























































Figure 3.1:  Lesional monocyte infiltration and inflammation are decreased in mCAT transgenic  Ldlr
-/-
 
chimeric mice.   
mCAT transgenic (mCAT)  Ldlr
-/-
 and littermate control  Ldlr-/- chimeric mice were fed the WD for 8 
wks, and aortic root lesions were analyzed as below.  Circulating Ly6
hi
 monocytes in the mice were 
labeled with green fluorescent beads in vivo prior to sacrifice (see text and Methods).  (A) Graph of 





), smooth muscle cells (SMCs), and CD3+ cells in aortic root lesions (n = 10 control vs. 9 














































Figure 3.2:  Lesional non-monocyte derived cell numbers, macrophage proliferation, macrophage egress 
and retention markers are identical in mCAT transgenic  Ldlr
-/-
 chimeric mice.   
Aortic root lesions of control  Ldlr
-/-
 and mCAT  Ldlr
-/-
 mice were stained and then quantified by 
fluorescence microscopic image analysis for (A) TUNEL
+
 (apoptosis) per mm
2
 lesion area;  (B) Left graph: 
Ki67
+
 cells among Mac3
+







mice were quantified for cell number before and each day 
for 3 days after addition of GM-CSF-containing media (n = 3 sets of macrophages/group).   (C) The 
indicated mRNAs, relative to Gapdh, were assayed using LCM-captured RNA from aortic root lesions of 





































































Figure 3.3:  Lesional monocyte infiltration and inflammation are decreased in mCAT transgenic  Ldlr
-/-
 
chimeric mice.   
Circulating Ly6
hi
 monocytes in the mice were labeled with green fluorescent beads in vivo prior to 
sacrifice (see text and Methods).  (A) Graph of beads number vs. lesion area (upper graph); 
Representative images, with intima outlined and bead-labeled cells depicted by arrows, and quantification 





 cells among lesional endothelial cells (n = 9 control vs. 8 mCAT 
mice/group; N.S., not significant); (C) Blood from the two groups of mice was analyzed for the indicated 
cell types by hemocytometer (upper three graphs) and analyzed for the indicated monocyte population by 







































































Figure 4:  Lesional inflammation and activation of NF-κB are decreased in mCAT transgenic  Ldlr
-/-
 
chimeric mice.   
(A) Relative level of lesional Mcp1, Tnfa, and Inos mRNA, relative to Gapdh, were assayed using LCM-
captured RNA from aortic root lesions of the two groups of mice (n = 5 mice/group; *P<0.05).  (B) The 
indicated mRNAs, relative to Gapdh, in the 2 groups of mice (n = 5 mice/group; *P<0.05).  (C) Plasma 
MCP-1 level as measured by ELISA (N.S., not significant).   
(D) Representative immunofluorescence images and quantification of nuclear NF-κB RelA p-S536 in 
lesional myeloid vs. non-myeloid cells (smooth muscle cells and endothelial cells) (n = 14 vs. 10 


















Quenching MitoOS in Cultured Macrophages Suppresses Inflammatory Cytokine and Chemokine 
Expression and Decreases Activation of the IKK-RelA Pathway 
To explore causation and mechanistic links among mitoOS, NF-κB, and MCP-1 expression, we turned to 







 mice, respectively).  MitoOS was quantified by FACS analysis of macrophages 
incubated the mitochondria-targeted fluorescence sensor of superoxide, MitoSOX.
104
  The first goal was 
to find activators of mitoOS that were relevant to atherosclerosis.  One possibility would be a circulating 
factor induced by hypercholesterolemia, but when macrophages incubated with serum from WD-fed vs. 
chow diet-fed Ldlr
-/-
 mice, the level of MitoSOX fluorescence was similar (Figure 5.1A, left graph).  We 
therefore tested molecules or other factors that are either known to accumulate in atherosclerotic lesions 
or mimic processes known to occur in these lesions (Figure 5.1A, right graph).  Six of these factors 
increased mitoOS in macrophages:  Lp(a), which is a highly atherogenic lipoprotein known to carry 
oxidized phospholipids (oxPLs)
105
; oxPAPC (1-palmitoyl-2-arachidonoyl-sn-phosphatidylcholine), which is 
a non-lipoprotein-bound oxPL
106
; the combination of an inducer of endoplasmic reticulum stress, 
thapsigargin, and another type of oxPL, KodiA-PC (1-[palmitoyl]-2-[5-keto-6-octene-
dioyl]phosphatidylcholine)
107
; 7-ketocholesterol (7KC), which is an oxysterol that accumulates in 
atheromata
108
; lipopolysaccharide (LPS), which is a model of toll-like receptor activation in 
atherosclerosis
109
 and oxidized LDL (oxLDL)
110
, which turned out to be the most potent activator of 
mitoOS in this screen.  In contrast, a minimally oxidized form of LDL (mmLDL)
111
 and two inflammatory 
cytokines, TNF-α and interleukin-1 (IL-1β), did not induce mitoOS in macrophages. 
 For the mechanistic studies that follow, we focused on two of the inducers, oxLDL and LPS.  We 
verified the increase in mitoOS by these stimulators using both non-nuclear 8-OHdG and MitoSOX and 
showed these signals co-localized with the mitochondria markers ATP5α and Mitotracker Green (Figure 
1.1A and Figure 5.1B).  Most importantly, MitoSOX fluorescence induced by LPS and oxLDL were lower 
in macrophages from mCAT-expressing mice (Figure 5.1C).  We then determined whether this model 
could mimic a major mechanistic finding in our in vivo studies, namely, that mCAT suppresses pro-
inflammatory cytokines and chemokines and RelA activation.  The data show that Mcp1 and Tnfa mRNA 





(Figure 5.1D).  The decrease of Mcp1 and Tnfa by mCAT was greatest at later time points, suggesting 
that mitoOS maybe most important for mediating sustained expression of these molecules.  Consistent 
with the specificity of the model, mCAT does not suppress Mcp1 in mmLDL-treated macrophages.    
We investigated a possible link between mitoOS and inflammation by examining NF-κB RelA 
(p65) activation.  As expected, LPS caused an increase in two markers of activation of this pathway, p-
Ser
177
-IκB kinase (IKK) β and p-Ser
536
-RelA.  Most importantly, both of these markers were decreased in 
mCAT-expression macrophages (Figure 5.1E).  OxLDL-induced p-Ser
536
-RelA was also decreased by 
mCAT (Figure 5.1E).  In contrast, the phosphorylation levels of two other LPS-TLR signaling molecules, 
mitogen-activate protein kinase (MAPK) p38 and c-Jun N-terminal kinase (JNK), were not suppressed by 
mCAT (Figure 5.2A).  As an important negative control for this mCAT effect, we tested mmLDL, which 
does not activate mitoOS (Figure 5.1A).  mmLDL was unable to activate RelA, and the induction of Mcp1 
was not affected by mCAT (Figure 5.2B).  Thus, the macrophages incubated with LPS or oxLDL capture 
the essential mechanistic features that were found in the macrophages of control vs. mCAT 
atherosclerotic lesions.   
 These macrophage models were then used to address a critical causation question, namely, 
whether restoration of the RelA pathway could blunt the ability of mCAT to suppress Mcp1 and Tnfa.  We 
began by testing our restoration strategies in control macrophages.  The first strategy used RelA 
transfection, which we found increased both p-RelA and also Mcp1 and Tnfa in response to LPS (Figure 
6.1A).  The second strategy used IKK transfection, which increased the level of p-IKK and p-RelA and the 
expression of Mcp1 (Figure 6.1B).  We then applied these strategies to control vs. mCAT-expressing 
macrophages.  In macrophages transfected with control vector, mCAT lowered both LPS-induced p-RelA 
and Mcp1 and Tnfa as above (Figure 6A, left half of blot and first pair of bars in each group in the graphs).  
In macrophages transfected with RelA, however, there was an increase in LPS-induced p-RelA, Mcp1, 
and Tnfa, and, most importantly, mCAT did not suppress the cytokine mRNA levels under these 
conditions (Figure 6.2A, right half of blot and second pair of bars in each group).  Similar results were 
obtained when restoration of the RelA pathway was accomplished using IKK transfection (Figure 6.2B) 





 Interestingly, Kanters et al.
112
 letion actually increased lesion 
area in WD-fed Ldlr
-/-
 mice.  Although the mechanism remains to be determined, macrophages from these 
mice, when stimulated with LPS in vitro, secreted lower levels of the anti-inflammatory/anti-atherogenic 
cytokine, interleukin 10 (IL-10).  In contrast, we found that the suppression of the IKK pathway by mCAT 
in macrophages was associated with a slight but significant increase in IL-10 (Figure 7A), which might 
contribute to the beneficial effect of mCAT.  In another study, consistent with our overall findings on the 
role of RelA in atherosclerosis, Goossens et al.
113 
demonstrated that myeloid deficiency of IκB, a negative 
regulator of RelA, promoted atherogenesis by enhancing leukocyte recruitment to the plaques.  Although 
this study did not probe mechanism in vivo, IκB deficiency in LPS-treated cultured macrophages was 
associated with an increase in the chemokine CCL5 but not MCP-1.  This finding contrasts with the 
effects of suppressing RelA via mCAT, which we showed decreases Mcp1 but not Ccl5 both in vivo and 
in the LPS-macrophage model (Figure 4B and 7B).   
        To test ROS-source specificity in activating RelA-MCP-1 signaling, we transfected macrophages with 
cytosolic catalase (cCAT), which we showed suppresses LPS-induced cytosolic ROS (cellROX) but not 
mitoOS (MitoSOX) (Figure 8A and 8B).   cCAT did not suppress RelA and actually enhanced the 
induction of Mcp1 and Tnfa mRNAs (Figure 8C), which is consistent with previous studies suggesting 
non-mitochondrial ROS can inhibit pro-inflammatory cytokine induction
114, 115
.  Thus, mitoOS has distinct 
roles in inflammatory signaling compared with other sources of cellular oxidative stress.   
These combined in-vivo and in-vitro data support the hypothesis that an important pro-
atherogenic mechanism of macrophage mitoOS is the enhancement of IKK/RelA signaling, leading to 

















































































































 mice have less LPS-induced mitoOS, Mcp1, 
p-RelA, and p-IKK.   
(A) Cultured macrophages from wild-type mice were pre-incubated with MitoSOX for 30 min and then 
incubated for 18 h with DMEM containing 10% of the following sera:  fetal bovine serum (FBS), serum 
from chow diet-fed Ldlr
-/-
 mice, or serum from WD-fed fed Ldlr
-/-
 mice (left graph); Cultured macrophages 
were incubated with MitoSOX for 30min and treated with the indicated stimuli for either 4 h (mmLDL) or 
12 h (other stimuli).  The doses were:  Lp(a) 25 μg/ml, oxPAPC 25 μg/ml,  KOdiA-PC 50 µg/ml, 
thapsigargin 0.5 μM, mmLDL 50 μg/ml, oxLDL 50 μg/ml, 7KC 35 μg/ml, IL- -α 40 ng/ml, 
LPS 100 ng/ml (Left graph); Cultured macrophages were The cells were then analyzed by flow cytometry, 
and the data were quantified as MitoSOX mean fluorescence intensity (n = 3 sets of macrophages/group; 
*P<0.05). (B) Representative images of macrophages stained with MitoSOX and then treated with LPS 
cubation times, the cells were stained with 




 columns of images 




 column of images, respectively.  Bars, 10 
μm for the first 4 columns of images and 2 μm for the fifth column.  The flow cytometry data are shown in 





macrophages are protected from LPS- and oxLDL-induced mitoOS (n = 3 sets of 
macrophages in each group).  (D) Time course of Mcp1 and Tnfa mRNA levels, relative to Gapdh, after 
LPS and oxLDL treatment (n = 3/group; *P<0.05).  (E)  Immunoblots showing decreased phosphorylation 




macrophages after 6 h of LPS or oxLDL 
treatment; also shown are total catalase and, as a loading control.  Densitometric quantification of the 
phospho:total ratio of RelA and IKK from the immunoblots is shown in the bar graphs (n number/group 




















Figure 5.2:  mCAT does not suppress p-P38 or p-JNK activation in LPS-treated macrophages or does not 
affect minimally oxidized LDL (mmLDL)-induced Mcp1 mRNA in macrophages.  






mice were incubated with 100 ng/ml LPS 
for the indicated times and then assayed by immunoblot for phospho- and total P38 MAPK, p-JNK, and β-
actin loading control. (B) Macrophages from WT mice were incubated with 50 mg/ml mmLDL for the 
indicated times and then assayed by immunoblot for NF-κB RelA (p- -actin loading control 






macrophages mice were incubated with 50 mg/ml mmLDL for 












































Figure 6.1:  Transfection of macrophages with RelA or IKK increases LPS-induced Mcp1.   
Macrophages were transfected with control plasmid (pcDNA3) or RelA-encoding plasmid (A) or IKK-
encoding plasmid (IKK) (B) and then assayed for the indicated proteins by immunoblot and for relative 

















































































Figure 6.2:  Restoration of RelA abrogates the difference in LPS or oxLDL-induced Mcp1 expression in 
control vs. mCAT-expressing macrophages.   
(A) Macrophages were transfected with control (pcDNA3) or RelA-encoding plasmid and then assayed for 
phospho- and total RelA by immunoblot, with GAPDH as the loading control, and Mcp1 mRNA by RT-
qPCR, relative to Gapdh, before and after 6 h of LPS treatment  (n = 3 sets of macrophages in each 
group).  (B) The indicated groups of macrophages were transfected with control or IKK-encoding plasmid 
and then assayed for phospho- and total IKK and RelA and for Mcp1 MRNA  before and after 6 h of LPS 
treatment (n = 3/group; *P<0.05).  (C) The indicated groups of macrophages were transfected with control 
or RelA-encoding plasmid and then assayed for phospho- and total RelA and for Mcp1 mRNA  before and 




































 mice were treated for 6 h with 100 ng/ml LPS and 
then assayed for relative Il10 and Ccl5 mRNA by RT-QPCR (n = 3 sets of macrophages/group; *P<0.05; 











































Figure 8:  Transfection of macrophages with cytosolic catalase does not decrease LPS-induced Mcp1 
and Tnfα.    
Macrophages were transfected with control plasmid (pcDNA3) or plasmid encoding cytosol-targeted 
human catalase (cCAT).  (A) Mitochondrial and cellular ROS were measured by mitoSOX and CellROX 
staining, respectively, and quantified by flow cytometry as mean fluorescence intensity (MFI).  (B-C) 
Control and cCAT macrophages were incubated with 100 ng/ml LPS for 1 or 3 h and then assayed for the 
indicated proteins by immunoblot and for relative Mcp1 and Tnfα mRNA levels by RT-QPCR (n = 3 sets of 
































In view of the association between markers of mitoOS and the progression of human atherosclerosis
80
 
and the importance of inflammatory macrophages in atherosclerosis, the goal of the current study was to 
provide causation data in vivo for the role of endogenous macrophage mitoOS in atherosclerosis and to 
explore mechanism.  Our data indicate that macrophage mitoOS is atherogenic and that a major 
mechanism involves activation of an NF-κB—MCP1 pathway.  Whether mitoOS in other lesional cell 
types also contributes to atherogenesis remains to be determined.
116-118
  In an elegant study, Sessa and 
colleagues
81
 showed that overexpression of thioredoxin-2 in endothelium lowered oxidative stress and 
enhanced production of NO in endothelial cells, improved endothelial function in aortic rings, and 
lessened atherosclerosis in Apoe
-/-
 mice.  Although this study did not examine mitoOS per se, the fact that 
thioredoxin-2 is localized to mitochondria raises the possibility that pro-atherogenic effects of mitoOS in 
endothelial cells might complement the effects revealed here for macrophages.  Moreover, Bennett and 
colleagues
25
 have shown recently that mitochondrial DNA damage independently of mitoOS can lead to 
pro-atherogenic changes in smooth muscle cells and monocytes.  In the context of that report and our 
finding that nuclear 8-OHdG becomes very high in the most advanced lesions, it is highly likely that non-
mitochondrial sources of oxidative stress are important in atherosclerosis, perhaps particularly so in 




Our mechanistic studies support a model in which lesional macrophage mitoOS promotes inflammation in 
general and MCP-1 induction in particular, which would then amplify the inflammatory milieu of lesions by 
promoting additional monocyte entry.   Although recent studies using Ccr2
-/- 
mice showed that MCP-1 can 
promote the release of Li6c
hi
 monocytes from the bone marrow
121
, MCP-1 can also contribute to 
monocyte entry into local sites of inflammation, including atherosclerosis
122-124
.  Indeed, we found here 
that mCAT expression in myeloid cells did not affect the level of plasma MCP-1 or the number of 
circulating monocytes, and we showed recently that injection of anti-MCP-1 neutralizing antibody into a 
similar model decreased monocyte entry into atherosclerotic lesions
94
.  Moreover, the level of other 
potentially atherogenic chemokines and their receptors, including CCR5/CCL5 (RANTES), 
CX3CR1/CX3CL1 (fraktalkine), and CXCL1/CXCR2
125-127





lesions.  Thus, suppression of the NF-κB—MCP-1—chemokinesis pathway is likely an important 
mechanism behind the decrease in lesion cellularity in macrophage-mCAT mice. 
 The data herein have also revealed an interesting link between mitoOS and IKK-RelA activation.   
Although a number of studies have shown that oxidative stress can activate NF-κB signaling
128-131
, the 
specific roles of different cellular sources of oxidative stress and how each may affect the NF-κB pathway 
and its various downstream targets remains to be fully explored.  In this regard, NF-κB target genes can 
be affected by NF-κB activation kinetics, cell type, nature of the stimulus, and cofactors
132, 133
.  In a study 
using murine embryonic fibroblasts and human peripheral blood mononuclear cells, the mitochondria-
targeted antioxidant Mitoquinone (MitoQ) was reported to suppress LPS-induced cytokine production, but 




 in macrophages actually showed a trend 
toward increased cytokine production
114
.  With regard to the MitoQ result, the authors hypothesized that 
the mechanism involved suppression of p38 and JNK MAPK signaling, but data specifically linking 
mitoOS to these MAPKs were not provided.  In another study, NADPH oxidase-deficient macrophages 
from gp91
phox
-null mice and CGD patients also produced increased inflammatory cytokines in response to 
LPS independently of NF-κB
115
.  These data are consistent with our finding that quenching non-
mitochondrial ROS by cCAT leads to enhanced LKPS-induced inflammatory cytokine induction without 
affecting NF-κB activation.  Thus, the source and/or intracellular location of oxidative stress can have 
distinct effects on activation of NF-κB signaling.    
 We provide evidence that mitoOS is linked to NF-κB through IKK, but exactly how mitoOS 
activates IKK remains to be determined.  Gloire et al.
134
 showed that H2O2 treatment of Jurkat cells led to 
activation of IKK and RelA through a pathway involving the phosphatase SH2-containing inositol-5'-
phosphatase 1 (SHIP-1).  Whether mitoOS enhances the activation of IKK through SHIP-1 remains to be 
determined.  Of interest, a recent study investigated the converse issue in macrophages, namely, 
activation of mitoOS by inflammatory signaling
26
.  The investigators showed that activation of certain Toll-
like receptors led to recruitment of TRAF6 and ECSIT (Evolutionarily Conserved Signaling Intermediate in 
Toll pathways) to mitochondria, ubiquitination of ECSIT by TNF receptor-associated factor 6 (TRAF6), 





However, whether the mitoOS generated by this mechanism then mediated or amplified downstream 
TLR-induced NF-κB signaling was not reported.    
 Oxidative stress in general has long been considered to be a therapeutic target for atherosclerotic 
vascular disease.  Enthusiasm was dampened, however, by studies in humans showing that vitamin E 
was not protective against human coronary artery disease
135
.  While these data might be interpreted as 
proof against the role of oxidative stress in atherosclerosis, a more likely explanation is that the choice 
and/or timing of anti-oxidant treatment was not optimal.  The association of mitoOS with human 
atherosclerosis progression and the causal and mechanistic insights provided by the current findings and 
previous studies raise the possibility that therapy targeted specifically to mitoOS may show benefit.  In 
this regard, Bennett and colleagues
136
 showed that systemic MitoQ administration decreased 
macrophage content and cell proliferation in the atherosclerotic lesions of fat-fed Apoe
-/-
 mice.  Although 
the mechanism behind these findings with regard to atherogenesis per se is difficult to ascertain in view of 
systemic metabolic effects of MitoQ administration, and although applicability to humans remains 
unexplored, continuing insight into the mechanisms and consequences of oxidative stress in 























Macrophage Mitochondrial Fission is Essential for Continued Clearance of Apoptotic Cells and Plays a 
















Mitochondrial morphology dynamics influence and integrate with multiple physiologic and 
pathophysiologic processes, including mitosis, mitochondria distribution, mitochondria metabolism, 
mitochondrial quality control (mitophagy), as well as mitochondrial oxidative stress and cell death 
(apoptosis and necrosis).
44-46
  Diseases such as pulmonary arterial hypertension, arterial restenosis, 
hypertension, Parkinson’s disease, obesity and diabetes have been associated with abnormalities in 
mitochondrial dynamics.
47-49
  They are mediated by several different GTPases.  Mitofusin 1 (MFN1) and 
Mitofusin 2 (MFN2) regulate outer membrane fusion, whereas optic atrophy protein 1 (OPA1) mediates 
inner membrane fusion.  Mitochondrial fission is mediated by the cytosolic molecule called dynamin 
related protein 1 (DRP1) and its non-GTPase receptor proteins such as fission protein 1(FIS1) and 
mitochondrial fission factor (MFF).   
Previous data have suggested that these GTPases play divergent roles in a cell type specific 
manner in atherosclerosis.  For example, Mfn2 mRNA was progressively reduced in the lesions of Apoe
-/-
 
mice artery during the development of atherosclerosis.   MFN2 suppresses VSMC proliferation both in 
vitro and in vivo in the mouse vascular injury models.
52
   Consistent with this idea, a study in rabbit 
reported that overexpression of MFN2 was associated with reduced atherosclerosis.
53
   MFN2 also 
activates the mitochondria apoptotic pathway by inhibiting AKT signaling.
137
   These two functions of 
MFN2 together contribute to atherosclerosis progression.  Interestingly, diabetic venous endothelial cells 
have increased mitochondrial fragmentation and a higher level of the mitochondrial fission protein Fis1, 
which could contribute to mtROS overproduction and enhance susceptibility to atherosclerosis.
54
   While 
these studies hint at some interesting associations between mitochondrial dynamics and atherosclerosis, 
more precise in vivo models and more in-depth mechanist studies are needed to address the functional 
significance of mitochondrial dynamics in atherosclerosis.   It is important to note that in myeloid cells, the 
dominant cell types in atherosclerosis, the roles of these GTPases are largely unclear.    
Fission creates smaller and more discrete mitochondria, which are more capable of generating 
reactive oxygen species, facilitating mitochondrial autophagy “mitophagy”, or accelerating cell 
proliferation.
49, 50, 138, 139
  Fission is mediated by DRP1, a cytosolic protein that on activation translocates to 





multimerizes to create a ring-like structure that constricts and divides the organelle.   DRP1 is ubiquitously 
expressed in all essential organs and cell types.   Whole body DRP1 knockout mice are embryonic lethal, 
and mice with neuronal specific deletion of DRP1 have impaired early brain development.  These data 
suggest its critical role in embryonic development, especially neuronal development.  DRP1-mediated 
mitochondrial fission has been reported to mediate cell apoptosis, but the role of DRP1 in cell death 
varies depending on cell type and physiological contexts.  Under conditions such as aging, 
neurodegeneration, and ischemia-reperfusion, DRP1 activation promotes excessive ROS production.   
With regard to vascular cells, DRP1-mediated mitochondrial mitotic fission permits hyperproliferation of 
VSMC.   In human aortic endothelial cells, DRP1 is upregulated upon high glucose challenge.   Such 
upregulation increases mitochondrial ROS production and mitochondrial fission.
54
   The specific functions 
of DRP1 in myeloid cells, in the setting of atherosclerosis have not been examined.     
Uncoupling protein 2 (UCP2) is a mitochondrial inner membrane protein and the dominant form of 
UCP that is expressed in Mφ and lymphoid system.   Its basic function is to uncouple the hydrogen 
gradient cross the mitochondrial inner membrane with ATP synthesis.  In this process, UCP2 lowers the 
ΔΨ and reduces mitochondrial ROS production.  UCP2 promoter polymorphisms in humans are 
associated with multiple pathological conditions, including obesity, diabetes, and atherosclerosis.
55-58
  










  Mechanistically, its athero-protective role is not well understood.  Recently, Ravichandran’s group 
discovered the essential role of UCP2 in continued uptake of apoptotic cells in phagocytes, through 
lowering mitochondria membrane potential ΔΨ.
140
  Whether its athero-protective effect depends on 
facilitating continued uptake of ACs and how the lower ΔΨ permits continued uptake of ACs are not clear.   
Given that GTPases-mediated mitochondrial dynamic changes have unique functions in 
individual cell types, we aimed to explore the role of DRP1-mediated mitochondrial fission in 
atherosclerosis, with a focus on myeloid cells (monocyte-derived Mφs).   In this study, we adopted a 
mouse model whose EXON II of DRP1 (a part of GTPase domain) was flanked by two loxP sites (Drp1
fl/fl 
mice).   By crossing this model with LysMCre transgenic mice, we conditionally knocked out DRP1 in 











mitochondrial fission in both early atherogenesis and advanced atherosclerosis.  We confirmed 






mice.  Our data thus 







transmission electron microscopy (TEM) analysis; (2) Suppression of Mφ mitochondrial fission does not 
affect early atherogenesis; (3) Inhibition of Mφ mitochondrial fission leads to a striking increase of necrotic 
core area and the accumulation of apoptotic cells, which are likely due to the defective phagocytic 
clearance of apoptotic cells (efferocytosis) in the advanced stage of atherosclerosis in vivo;  (4) DRP1-
deficient Mφs are defective in clearance of apoptotic cells both in vivo and in vitro. (5) The phagocytic 
deficiency in DRP1-deficient Mφs is associated with a reduced level of uncoupling protein 2 (UCP2), a 
mitochondria protein required for continued uptake and clearance of dead cells in phagocytes.  We 
conclude that DRP1-mediated mitochondrial fission in Mφs promotes the continued clearance of apoptotic 
cells and thereby blocks necrotic core formation in advanced atherosclerosis.   In terms of 
mechanism, we hypothesize that mitochondrial fission stabilizes UCP2 in the inner membrane of 
mitochondria.  Further studies are required to elucidate how DRP1-UCP2 pathway maintains the 



















Animals and Diets 
C57BL/6J (000664) and Ldlr
-/-
 (002381) mice on the C57BL/6J background were purchased from Jackson 
Laboratory.  DRP1 floxed mice were generated as described previously
141
  and were backcrossed >10 
times onto the C57BL/6J background.   DRP1 floxed miced were crossed with LysMCre mice
93
 to 











 male mice, at 8weeks of age , were placed on a Western-type diet (TD88137; 
Harlan Teklad) for the indicated periods of time.    
 
Atherosclerotic Lesion Analysis 
For morphometric lesion analysis, sections were stained with Harris’ hematoxylin and eosin. The total 
lesion area and necrotic area were quantified as previously described.
86
   For immunostaining, specimens 
were immersed in OCT and 6-µm sections were prepared and placed on glass slides.  The sections were 
fixed and permeabilized with ice-cold acetone for 10 min.  Paraffin-embedded specimens were sectioned, 
de-paraffinized with xylene, and rehydrated in decreasing concentrations of ethanol.  TUNEL staining 
(Roche TMR in situ cell death kit, Cat No. 12 156 792 910) was performed according to manufacturer’s 
instruction.   Basically, sections were incubated with TMR reagents @ 37 °C for 30 mins, and then wash 
with PBS x 3.  Sections were then blocked with 10% goat serum for 30 mins and incubated overnight at 
4C with anti-Mac-3 (BD Clone M3/84, 1:200), The sections were then incubated with anti-rat secondary 
antibody (Ven-conjugated with Alexa 488 (Life Technology).  Sections were counter-stained with DAPI to 
identify nuclei before mounting.  
 
In situ Efferocytosis Assay in Atherosclerosis Lesions 
Following established procedures described previously.   Efferocytosis was determined in situ by counting 
the number of free versus Mφ-associated apoptotic cells in individual lesion sections.  Apoptotic cells 
were considered “free” when they were not surrounded by or in contact with Mφs, as described in detail in 






Measurement of cell clearance in thymus 
8wk old female mice (8/group) were intraperitoneally injected with 500ul PBS with 250μg dexamethasone 
(Calbiochem) dissolved in DMSO.   18 hrs after injection, mice were sacrificed and thymuses were 
extracted.  For quantification of thymic cellularity, half leaf of the thymus was disrupted mechanically.  
Thymocytes were resuspended in the same volume of staining buffer (BD Bioscience 554656) and 
counted under cytometer.    Half of the suspended cells were fixed in PBS (PH = 7.0)-buffered 4% PFA 
for 15 min at room temperature, and were then permeablized with 0.1% Triton in 1% citrate buffer at 
roome temperature for 8 mins, washed with PBS, incubated with TUNEL staining reagents (Roche, TMR) 
for 10 mins @ 37°C,  and analyzed by FACS.  The rest half of the suspension was stained with annexin V 
conjugated with Alexa 488 (life technology) and subjected to FACS analysis.  The other half of the thymus 
was fixed in formalin and embedded in paraffin.   Thymic sections on glass slides were stained using the 
In situ Cell Death Red kit according to manufacturer’s instructions (Roche).  Sections were counter 
stained with the Mφ marker F4/80 (ABD Serotec clone Cl: A3-1) before being mounted with Prlong 
Antifade plus DAPI medium, and analyzed using an Olympus IX-70 inverted fluorescent microscope 
equipped with a mercury 100-W lamp (CHIU Technical Corp.), filter wheels, fluorescent filters (Chroma), 
an Olympus LCPlanF1 x 40 objective, DP Manager Basic imaging software (version 3.1; Olympus), and 
an Olympus DP71 CCD camera.    
Mφ phagocytosis assay  
Cultured peritoneal Mφ (1.5 x 106) were placed in a 24-well plate (phagocytes) and labeled with calcein 
green (Life Technology, C34852).  Apoptotic cells were induced as follows:  Jurkat cells were irradiated 
with UV for 10 mins, then waited for 4 hrs; peritoneal Mφs were treated with 7-ketocholesterol (50ug/ml) 
for 18 hrs or oxLDL (50ug/ml) for 24 hrs.  Apoptotic cells were labeled with annexin V conjugated with 
Alexa 647.   In most experiment apoptotic Jurkat cells were then added to phagocyte at 2.5 : 1 ratio, 
unless otherwise noted.  Apoptotic Mφs were added at 1:1 ratio.   At the end of incubation, cells were 
vigorously washed with cold PBS 3 times, and lifted for FACS analysis.  FITC positivity was used to 
distinguish free unbound targets from phagocytes.  The “double-positive” cells represent targets engulfed 





Immunofluorescence staining in cultured Mφs 
Cultured Mφs or MEFs were plated on cover slide bottom non-tissue culture coated dishes at relative low 
confluence.  They were washed with PBS, and fixed with ice-cold acetone on ice for 5 mins.  After two 
washes with PBS, cells were incubated with blocking buffer (PBS with 10% goad serum) for 1 hr.  Cells 
were than incubated with antibodies against DRP1 (BD clone 8/DLP1, 1:200 dilution) and COX IV (Cell 
signaling,  4844, 1:200 dilution) @ 4°C overnight,  followed by the incubation with Alexa 488-conjugated 
anti-mouse and  Alexa 594-conjugated anti-rabbit 2
nd
 antibody.   The cells were then imaged by confocal 
microscope (NIKON A1 Confocal with 100X oil objective).     
 
RT-QPCR 
RNA was extracted from cultured single layer of peritoneal Mφs using the RNeasy Micro Kit (Qiagen).  
The purity of the RNA was measured by absorbance at 260 and 280 nm using NanoDrop 
spectrophotometry (Thermo Scientific).  RNA with an A260/280 of >1.8 was used for cDNA synthesis with 
M-MLV reverse transcriptase (Life Technology).  QPCR was performed in a 7500 Real-Time PCR system 
(Applied Biosystem) using SYBR green chemistry.  Mouse Dlp1 gene primer was designed targeting 
EXON 2, which was flanked by two loxp sites.   Forward :  ATAAGCTGCAGGACGTCTTC; Reverse:  
TGACCACACCAGTTCCTCT.   
 
Transmission Electron Microscopy 










 mice were fixed with 2.5% glutaraldehyde in 
0.1 M Sorenson’s buffer (pH 7.2) for 1 h, post-fixed with 1% OsO4 in 0.1M Sorenson’s buffer, and 
embedded in Lx-112 (Ladd Research Industries, Burlington, VT) and Embed-812 (EM Science, Fort 
Washington, PA). Thin sections were prepared on a MT-7000 RMC cryoultramicrotome, stained with 
uranyl acetate and lead citrate, and examined by transmission electron microscopy using a JEOL JEM-
1200 EXII.  Cells full of lipid droplets (singly membrane vacuoles with medium electron density) were 
defined as foam cells.    Mitochondria are recognized as cytosolic double membrane structures with 







Falcon tissue culture plastic was purchased from Fisher Scientific.  Tissue culture media, cell culture 
reagents, and heat-inactivated fetal bovine serum (FBS) were from GIBCO.  Jackson ImmunoResearch 
for horseradish peroxidase-conjugated goat anti-rabbit IgG, donkey anti-mouse IgG secondary antibodies.    
 
 
Plasma Glucose, Cholesterol and Triglyceride Measurements 
Fasting blood glucose levels were measured using ONETOUCH Ultra strips after 12 h of fasting.  Total 
plasma cholesterol, HDL-cholesterol, and triglyceride were measured using commercially available kits 
(Wako Pure Chemical Industries).  Pooled plasma from 3 mice was used to obtain FPLC lipoprotein 
profiles.  Profiles were obtained using FPLC gel filtration and a Superose 6 column (Amersham 
Pharmacia) at a flow rate of 0.2 ml/min, followed by cholesterol assays of the fractions.  
 
Statistics 
Values are given as means ± S.E.M. unless otherwise noted, with n number for each experiment listed in 
the figure legends; absent error bars in the bar graphs signify S.E.M. values smaller than the graphic 
symbols.  Comparison of mean values between two groups was usually evaluated by a Student t-test.  
When the data did not fit a normal distribution, the Mann-Whitney U rank-sum test was used.  
Comparison of multiple mean values was evaluated by ANOVA.  Linear regression analysis was 
conducted using SigmaPlot 12.5 software.  For all statistical methods, a P value less than 0.05 was 




























mice to specifically delete DRP1 in lysozyme-expressing myeloid cells.  These mice were 
further crossed with athero-prone mice (Ldlr
-/-




 mice are 
viable and show no gross abnormalities during their development.  I found that Drp1 mRNA level in 




 mice was reduced by more than 80% compared with littermate 
controls (Drp1
fl/fl
) (Figure 1A), while Drp1 mRNA level the smooth muscle cells isolated from the aorta was 
similar between the two groups of mice.  As shown in Figure 1B, control Mφs express DRP1 (green) in 
the cytosol or at the ends of newly fragmented mitochondria.   Their mitochondria (stained with COXIV in 





Mφs have barely detectable DRP1.  Their mitochondria are elongated, inter-twined, and more likely to 
cluster around peri-nuclear region, as shown in the boxed region of the representative images.  In the 






 mice after 12 wk WD feeding, Mφs have significantly longer 




 lesions (Figure 1C).  Mitochondrial morphology 
of neighboring smooth muscle cells (SMCs) are identical in the two groups (data not shown).  Thus, with 
lysmCre expression, the deletion of DRP1 is marked and specific to myeloid cells.  More importantly, 
deletion of DRP1 is sufficient to cause mitochondrial morphology changes.    
 Further, we examined the levels of GTPases that control mitochondrial dynamics.  The levels of 






mice.  Interestingly, 
the outer membrane fusion protein MFN-1 is robustly decreased.  OPA1 is the inner membrane fusion 
protein.  Constitutive OPA1 cleavage by YME1L and OMA1 at two distinct sites leads to the accumulation 
of both long and short forms of OPA1.
142
  The long form of OPA1 is required for fusion, while the short 
form promotes mitochondrial fragmentation.
143
  The long isoform is dominant in WT Mφs, while OPA1 is 
excessively processed to short isoforms in DRP1-deleted Mφs.  The decreased MFN-1 and excessive 
processing of OPA1 might be a compensatory effect in cells whose fission is blocked.  MFN2 is another 





It is also the critical component of ER-mitochondria association membrane (MAM), the essential structure 
facilitating ER mitochondria interaction.  Interestingly, MFN2 levels are comparable in the two groups of 
Mφs.  Thus, GTPases that mediate mitochondrial fusion are compensatorily down-regulated or 
inactivated in DRP1 deficient Mφs.   Here, we use mitochondria volume indicators pyruvate 
dehydrogenase E1 beta subunit (PDH1α) and ATP synthase subunit α (ATP5α) as mitochondria loading 
controls.   DRP1 deficient Mφs have similar mitochondrial volume as control Mφs, suggesting that 




















































Figure 1 A 
Peritoneal macrophages 
Cultured peritoneal macrophages 






































Figure 1: DRP1 deficient Mφs have elongated mitochondria and altered expression of molecules 
regulating mitochondrial dynamics.   






 mice were assayed for 
Drp1 mRNA, relative to β-actin by RT-QPCR (n = 3/group; * P<0.01).  (B)  Peritoneal Mφs were 
immunostained using antibodies against DRP1 (green) and the mitochondria marker cytochrome C 
oxidase IV (COX IV) and viewed by fluorescence microscopy.  The 2
th
 column of images is higher 
magnification of the boxed areas in 1
st





 Mφs displays a typical peri-nuclear located mitochondria clustering.  Bars, 5 
μm for the 1
st
 column and 1 μm for the 2
nd











 mice after 12 wk WD feeding were subjected to transmission electron microscopy 
(TEM) analysis (100000X).  Representative images of lesional Mφs enriched with lipid droplets (blue 
arrowheads), and mean length of mitochondria (red arrows) is quantified in the graph b helow (Bar, 


























Mφ DRP1 Deletion Plays Negligible Roles in Early Atherogenesis. 
Having confirmed the deletion of DRP1 in our model, we explored the role of Mφ specific DRP1-mediated 
mitochondrial fission in early atherogenesis in the Ldlr
-/-
 background.   After 8 wks WD, cross sections of 










 mice were analyzed.  Total 
lesion areas of the two groups are similar, suggesting a negligible role of Mφ-specific DRP1-mediated 

























































 mice were fed the WD for 8 wks, and aortic root lesions 
were analyzed.  Representative H&E-stained aortic root lesions, with the intima marked by dotted lines, 
















Deficiency in Mφ DRP1 Promotes Lesion Necrosis and Apoptotic Cells Accumulation 
We further examined the role of Mφ specific DRP1 in advanced atherosclerosis, with a focus on necrotic 
core formation and lesional cell apoptosis, the key features of clinically dangerous atherosclerotic plaques 











 mice.  More strikingly, % of necrotic 






 lesions, which strongly 
indicate that the KO lesions are more advanced and more necrotic (Figure 3A).  The larger necrotic areas 
are associated with more apoptotic cell accumulation in the DRP1 deleted lesions (Figure 3B), suggesting 
that deletion of DRP1 in Mφs lead to a more advanced and vulnerable lesion phenotype.   
Accumulation of apoptotic cells could be due to either more cell apoptosis or less clearance of 
apoptotic cells by phagocytes (efferocytosis).  As DRP1 has been suggested to mediate cell death, we 
first assayed Mφs apoptosis by treating them with athero-relevant apoptosis inducers:  7 ketocholesterol 
(7KC) or oxidized LDL (oxLDL) in vitro (Figure 3C).   DRP1-deleted Mφs undergo a similar rate of 
apoptosis as control Mφs.  Then we tested whether DRP1-deleted Mφs were defective in efferocytosis in 
the atherosclerosis lesions.
144
  Specifically, we measure the ratio of free-to-Mφ-associated apoptotic cells 
in lesions by staining for nuclei, TUNEL, and Mφs.  In this procedure, apoptotic bodies are detected as 
TUNEL-positive nuclei (in red), whereas Mφ efferocytes are detected as cells having cytoplasm with 
Mac3 positivity (a lesional Mφ marker, in green).  TUNEL-positive nuclei that do not overlap with the Mac3 
signals are considered “free”, whereas TUNEL-positive nuclei that overlap with Mac3 signals are 
considered “Mφ-associated”.   The images show examples of this procedure in Figure 3D.  The upper and 
middle images show an apoptotic body (ie, TUNEL-positive nucleus; arrows). The bottom left image also 




 lesions, the apoptotic body is in close 







lesions is not closely associated with any Mφ (“free”), shown in the right column.  Free versus Mφ-
associated apoptotic cells were quantified blinded in lesions from the two groups of mice.  Quantitative 


































































































 mice were fed the WD for 12 wks, and aortic root lesions 
were analyzed as below.  (A) Representative H&E-stained aortic root lesions, wiith the necrotic area 
boundary marked by yellow dotted lines (Bar, 40 μm), and quantification of total lesion area and necrotic 
area (n = 14 vs. 12 mice; * P < 0.05).  (B) The lesions were stained with apoptosis marker TUNEL (red 
and depicted by arrows), Mφs (green, Mac3) and nuclei (blue, DAPI).  Representative micrographs of 
TUNEL (the left column) and merged images (the right colume), and data were quantified as the 
percentage of TUNEL
+
 cells among all the Mac3+ cells in the graph on the right (Bar, 20 μm; n = 14 vs. 






mice were treated with 
vehicle (Veh), 7-ketocholesterol (7KC, 35g/ml) and oxidized LDL (oxLDL, 50g/ml) for 18 hrs, and assayed 
for apoptosis (Annexin V) by FACS (n = 3 sets of Mφs in each group; N.S., none significant).  (D) 
Examples of nuclear (blue; DAPI), TUNEL (red), and Mφ Mac3 (green) staining to differentiate Mφ-











 mice, respectively.  Arrows indicate apoptotic bodies.  
Quantitation of the free-to-Mφ-associated ratio of apoptotic cells in the lesions of the 2 groups of mice 

















Mφ DRP1 Deletion Does not Lead to Pro-atherosclerosis Metabolic Changes  
We further characterized the systemic metabolic parameters that might contribute to atherosclerosis 
progression.  Glucose, triglyceride and cholesterol metabolisms are similar between the two groups.  







(Figure 4).  Because higher HDL levels protect against atherosclerosis, the changes in HDL level cannot 






 mice. Thus, we conclude that the change 






 mice.  Why and how the deletion of DRP1 in Mφs leads to higher HDL level in the plasma is an 





















































 mice.  
Plasma lipids, lipoproteins, fasting glucose, body weight, and FPLC profile of lipoprotein-cholesterol were 
assayed for the two groups of mice (n = 14 vs. 12 mice;  N.S., not significant; * P = 0.008). 









 Mice in vivo   
Based on our findings in the atherosclerotic lesions, we decided to examine the efferocytic capability of 
DRP1 null macrophages under the condition when a significant population of cells within a tissue is 
undergoing apoptosis.  Injection of dexamethasone (Dex) in mice induces rapid and synchronized 
thymocyte apoptosis and the subsequent clearance of apoptotic cells by the resident and infiltrated Mφs 
(Figure 1A).  Normally after 18 hrs dexamethasone injection,  the thymus starts to shrink if the clearance 





mice does not decrease after Dex injection (the upper images, Figure 5B).   Consistent 





compared to the controls (the lower graph, Figure 5B).   Then we analyzed cell apoptosis by two different 
assays:  annexin V staining, a measure of phosphatidylserine (PS), and TUNEL staining (a measure of 










mice, the apoptosis of thymocytes in two groups of mice should be same.  Therefore, 




mice is because of impaired clearance.  The first step for 
phagocytes to eat ACs is to migrate toward ACs that release “find-me” and “eat-me” signals.   We found 





mice are defective of clearing apoptotic thymocytes in vivo, and the defect is not due to 
































Figure 5    
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 mice.    
(A) Schematic of the assay for assessing clearance of apoptotic thymocytes in vivo.  Mice were 
intraperitoneally injected with 250μg dexamethasone.  18 hrs later, mice were sacrificed, and one leaf of 
thymus was used for FACS analysis, and the other was used for histology analysis.  (B) Representative 






 mice injected with PBS or 250μg 
dexamethasone.  Quantitations of thymus cellularity and weight were shown in the graphs below.  (C) 




 cells per thymus by FACS.  n = 8 mice/group for annexin V 
staining; n = 4 mice/group for TUNEL staining analysis.  (D) Paraffin embedded thymuses were stained 
with TUNEL (red), Mφ F4/80 (green).   Representative immunostaining of TUNEL (lane 1-2), F4/80 (lane 
3) and merged staining (lane 4) from thymic sections.  The edges of thymus were outlined by yellow 
dotted lines, and TUNEL
 
positive areas were depicted by arrows.  Images of lane 2-4 were the higher 
magnification of the boxed area in the images of lane 1.  Images of lane 5 were the higher magnification 
of the boxed area in the images of lane 4.  Bars, 80 μm for lane 1; 20 μm for lane 2-4; 4 μm for lane 5.  (E) 






 mice were seeded on trans-well filters (pore size = 
8μm), and the migratory capacity was tested under the indicated conditions for 4 hrs.  Apoptotic MEFs 
were generated by UV irradiation for 10mins.  4 hrs later, more than 60% MEFs showed annexin V 
positivity.  Mφs on trans-well filters were then incubated with apoptotic MEFs for another 4 hrs.    Medium 
only or MEFs without irradiation were used as negative controls.    Medium with 10ng/ml MCP-1 was the 














Defective Uptake of Apoptotic Cells in Mφs Lacking of Mitochondrial Fission in vitro 
To explore the molecular and cellular mechanisms of efferocytosis deficiency in DRP1 deleted Mφs, we 
performed Mφ efferocytosis assay in vitro.  Specifically, we incubate peritoneal Mφs (phagocyte, labeled 
with calcein green) with apoptotic cells (ACs, labeled with annexin V Alexa-647 conjugated) for the 
indicated time periods at 37°C.  ACs are UV-irradiated Jurkat cells, 7-KC and oxLDL treated 
macrophgaes.   Phagocytes are washed three times with PBS, lifted and subjected to FACS analysis.   
Schematic of FACS analysis of phagocytes engulfing AC and without AC is demonstrated in Figure 6A.   
Data are quantified as the population of phagocytes engulfing AC among all the phagocytes.   Consistent 




Mφs is significantly impaired in vitro 
(Figure 6B, the upper three graphs).  Moreover, the defect of taking up ACs is not restricted to specific 
cell types or apoptotic stimuli.  Phagocytes can continuously take up apoptotic cells and lead to the 





Mφs, suggesting the continued uptake of apoptotic cells is impaired with DRP1 
deletion (Figure 6B, the lower two graphs).  We further perform dose curve and time course experiments, 
by increasing the AC to phagocyte ratio or prolonging the incubation time.  Both experiments indicate that 
DRP1 deficiency does not affect the initial AC uptake, but impairs the continued uptake of ACs after 
prolonged incubation or under the conditions where the AC to phagocyte ratio is high (Figure 6C). 
Collectively, the in-vitro data support the notion that DRP1 is required for continued uptake of ACs in Mφs.   
We further asked whether the continued uptake of ACs relied on mitochondrial fission or the other 
functions of DRP1 than fission.  To address this question, we used siRNA to knockdown DRP1’s docking 
protein FIS1.  FIS1 is located in the outer membrane of mitochondria, and DRP1-mediated outer 
membrane fission depends on its binding to FIS1.    As we have expected, more cells with siFIS1 have 
long or net-like mitochondria relative to scrambled siRNA treated cells.  Such morphology phenotype is 
less pronounced than cells treated with siDRP1 (Figure 6D), which is consistent with previous reports in 
other cells types than Mφs.
145
  Mφs with siFIS1 are also defective in continued uptake of ACs in vitro 
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Figure 6:  Impaired uptake of ACs in Mφs with mitochondrial fission deficiency.    
(A) Schematic of the FACS assessing Mφ efferocytosis in vitro.  Cultured peritoneal Mφs (phagocyte) 
were incubated with apoptotic cells (ACs) for 45 mins and then lifted for FACS analysis.  ACs were 
generated as below: 4 hrs after Jurkat cells were irradiated by UV for 10 mins; Mφs treated with 7-
ketocholesterol (7KC, 35 μg/ml) for 18 hrs; or Mφs incubated with oxLDL (50 μg/ml) for 20 hrs. ACs were 
stained with annexin V conjugated with Alexa 647 for 30mins before being added to phatocytes, which 
were labeled with calcein green (FITC).   Alexa 647 and calcein green double positive cells were 
phagocytes engulfing ACs.  Data were quantified as the percentage of phagocytes with AC among all the 
phagocytes, or mean fluorescence intensity (MFI) of annexin V per phagocyte as measures of efferocytic 
capacity.   (B) Quantification of % of phagocytes taking up AC (upper three graphs); Mean fluorescence 
intensity (MFI) of AC per phagocyte (lower two graphs).  (C) Mφs were incubated with AC (UV-treated 
Jurkat cells) for the indicated time (the left graph), or incubated with ACs at the indicated ratio (the right 
graph) for 45 mins.  Efferocytosis was assayed by FACS.  (D) Mφs were transfected with scrambled 
(SCR) or Drp siRNA (siDRP1) or Fis1 siRNA (siFIS1) for 84 hrs.  Total cell lysates of Mφs treated with 
indicated siRNAs were assayed for total DRP1 and Fis1.  ATP5a and β-actin were used as mitochondria 
volume and sample loading controls (the left blots).  Representative images of mitochondria morphologies 
in Mφs treated with indicated the siRNAs (the right images).  The right column is the higher power 
magnifications of the boxed areas in the left column.  Bars, 5μm in the left column; 0.5μm in the left 
column.  (E)  Mφs treated with indicated the siRNAs were loaded with UV-treated Jurkat cells for 45 mins.  
The percentages of phagocytes with ACs and MFI of AC per phagocyte were quantified in graphs.  * P < 
















 Mφs is Defective of Engulfing Cellular Materials with Metabolic Load   
Clearance of ACs by phagocytes is a complicated process.  It starts from the release of “find-me” signals 
from ACs.  After phagocytes sense those “find-me” signals, they migrate toward and then bind to ACs 
who present “eat-me” signals on the cell surface.  These signals are specific markers that can be 
recognized by engulfing receptors on phagocytes.  Once activated, these engulfment receptors signal 
intracellularly to mediate the physical rearrangement of the phagocyte cytoskeleton required for corpse 
uptake.   To understand why DRP1 deficiency leads to efferocytosis deficiency, we first tested cell 
migration capabilities.  We found DRP1 deficiency was not associated with impaired cell migration, as 
shown in Figure 5E.    Then we determined whether DRP1 deficiency impaired binding. Phagocytes were 
put in the cold (4°C) or incubated with an inhibitor of cytoskeleton rearrangement, cytochalasin D.  Under 
these conditions, phagocytes only bind to AC but do not start the engulfment process.   We found that two 
groups of cells had comparable binding capability in both conditions (Figure 7A).    Then we examined the 






Mφs.  Interestingly, DRP1 deletion does not affect 
the uptake of IgG-opsonized latex beads, while DRP1 deletion robustly impairs the engulfment of IgG-
opsonized sheep red blood cells (sRBCs) (Figure 7B),  Engulfment of synthetic latex beads and cellular 
material (ACs or opsonized living cells) share common cytoskeleton rearrangement machinery.  
Therefore, these data suggested that common cytoskeleton rearrangement machinery is intact in DRP1 
null Mφs.  The difference between beads and cell engulfment is that the cellular materials add a 
“metabolic load” to the phagocytes, and how phagocytes handle such metabolic load may affect the 
continued engulfment.  Taken together, fission deficiency specifically impairs the engulfment of materials 



























 Mφs.   
Efferocytosis was assayed by FACS after cells were incubated in the following conditions:  (A) pre-treated 
with cytochalasin D (5μM) for 30 mins and then incubated with ACs at 37°C for another1 hr; or incubated 
with ACs at 4°C for 1 hr.   (B) Incubated with IgG-opsonized sRBCs or IgG-opsonized synthetic beads 
(4.5 μm) synthetic latex beads for 1 hr at 37°C.   The ratio of cell/beads to phagocyte is 10 to 1.  * P < 





Figure 7    A    













 Mφs Have Reduced Level of UCP2 and Uncontrolled Elevation of ΔΨ  
Uncoupling protein 2 (UCP2) is the proton carrier in the inner membrane of mitochondria.  Instead of 
using the proton gradient to make ATP, UCP2 uses the proton gradient to generate heat.  In this process, 
UCP2 acts to lower mitochondria membrane potential ΔΨ and prevent mitochondria hyperpolarization.   
Recently, Ravichandran’s group has reported that UCP2 is upregulated after Mφs take up ACs but not 
synthetic beads.  UCP2 is required for continuous uptake of ACs through lowering mitochondrial ΔΨ.  
Moreover, UCP2
-/-
 atherosclerosis lesions have same phenotypes as DRP1 null lesions, including larger 
lesion sizes and more AC accumulation.   Thus, we reasoned that UCP2 and DRP1 maybe in the same 





lower level of UCP2 after taking up ACs (Figure 8A).  Associated with the reduced level of UCP2 
induction, the ΔΨ of phagocytes with mitochondrial fission deficiency is significantly elevated (Figure 8B).   
Taken together, these data demonstrate that mitochondria fission (mediated by DRP1 and FIS1) is 
required for UCP2 induction.  The increased UCP2 will prevent the extensive elevation of ΔΨ and enable 





































Figure 8:  Impaired UCP2 induction and uncontrolled ↑ΔΨ in Mφs lacking of mitochondrial fission.   






mice were incubated with ACs (7KC treated Mφs) 
for the 4 hrs.  Free ACs were washed away with PBS and cell lysates of the phatocytes were assayed for 
total UCP2 and the loading control β-actin.  (B) Mφs were incubated with ACs for 45 mins.  Relative ΔΨs 
of phagocytes engulfing vs. non-engulfing ACs were measured by MitoDeep Red.  MFI of MitoDeep Red 
was normalized to non-engulfing phagocytes treated with scrambled siRNA (the left graph); non-engulfing 
Cre
-/-
 phatocytes (the right graph).   * P < 0.05.  n = 3 vs. 3 wells/group.   
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Mφs are also called “macrophagocytes” because they are highly specialized in removal of dying or dead 
cells and cellular debris (efferocytosis).  Normally, the dying cells are quickly recognized and removed by 
phagocytes to prevent inflammation and keep tissue homeostasis.   However, under such chronic 
conditions as atherosclerosis, obesity and auto-immune disorders, the efferocytic system is impaired.  In 
atherosclerosis, various induced mutations or metabolic disorders that cause defective efferocytosis lead 
to increased necrotic core formation, increased inflammation and more advanced lesions in mouse 
models.
144, 146, 147
  However, why efferocytosis becomes inefficient during the advanced stage of 
atherosclerosis is unclear.   
Exploring the roles of mitochondrial dynamics and their functional significance has recently 
become a popular and intriguing topic.  However, the specific role of mitochondrial dynamics in Mφs has 
not been studied yet.   In this study, we used a genetic mouse model to investigate the role of DRP1-
mediated mitochondria fission in Mφs.  We have found that DRP1 is required for continued uptaking ACs 
both in vitro and in vivo.  Additionally, we tested its functional significance in the setting of advanced 
atherosclerosis, and we showed that mitochondrial hyperfusion lead to increased necrotic core formation 
and apoptotic cell accumulation.  To our knowledge, this is the first study to link mitochondria dynamics to 
the phagocytic function in phagocytes.    Our study further implied that mitochondrial dynamics could be a 
novel therapeutic target to maintain the efferocytic capacity in advanced lesions.   To test this, we plan to 
explore the mitochondrial dynamic changes during the natural progress of the disease.  We will start from 
the murine athero models, with a focus on mitochondria morphology and expression/activity of molecules 
that regulate mitochondria fusion/fission in lesional Mφs and/or circulating monocytes.  Further, we will 
continue examining the mitochondria morphology in human lesions, and/or in circulating monocytes.  If 
mitochondrial hyperfusion does occur, we would like to understand the following questions:  (1) Why does 
hyperfusion happen?  (2) Does hyperfusion cause efferocytosis deficiency in advanced atherosclerosis?  
(3) Is the inhibition of hyperfusion sufficient to maintain efferocytic efficiency and to prevent necrotic core 
formation?  
Mechanistically, our study further revealed an unexpected association of mitochondria dynamics 





uptake of ACs, and therefore the current working model is shown in Figure 9.  To consolidate this working 
model, we will test whether the restoration of UCP2 or pharmacological prevention ↑ΔΨ can correct the 
efferocytic deficiency in DRP null Mφs.   
 The most interesting question in this model is the link between DRP1 depletion and reduced level 
of UCP2.  Our preliminary data indicate that UCP2 mRNA level is about two-fold elevated in DRP null 
Mφs (data not shown), suggesting that this reduction in UCP2 protein involve a post-transcriptional 
mechanism.   It is known that UCP2 has a high turnover rate, and its degradation is mediated by UPS 
(ubiquitin-proteasome system).
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  Thus, one possibility is that DRP1 deletion leads to the enhanced 
degradation of UCP2 by UPS.  To test this hypothesis, we plan to pharmacologically inhibit protein 
translation and measure the degradation rate of UCP2 in two groups of Mφs.  If the degradation rates are 
different, we will further examine if the UPS-mediated UCP2 degradation is accelerated with the deletion 
of DRP1.  If the degradation step is intact, we can test the less likely hypothesis that DRP1 deletion 
decreases UCP2 translation or decreased post-translational mitochondrial import.  Besides, it is possible 
that DRP1-UCP link also exists in other disease models.  In the past twenty years, the essential roles of 
different family members of uncoupling protein have been suggested in a number of physiological and 
pathological conditions, including the regulation of fatty acid metabolism and insulin secretion.   It would 
be very interesting to explore whether DRP1-UCP link is also essential under these conditions.   
Another interesting point in this model is the link of DRP1 deletion (UCP2-/- or ↑ΔΨ) to the defect 
of continuous uptake of substances with a metabolic load.  We showed that DRP1 deletion does not 
affect the continued uptake of synthetic latex beads, but impairs the ability to take up sRBCs and ACs.   
Thus, we reasoned that how the phagocytes handle the excess metabolic burden acquired from the 
ingested corpse, such as cholesterol, lipids, fatty acids and proteins, might affect the long-term 
engulfment activity.  Mitochondrial fission, UCP2, or ΔΨ could be the key player to regulate this process.   
There are several hypotheses we are planning to test.  (1) Existing evidences suggested that LXR and 
PPAR are activated during AC clearance, via the sensing of the lipids and cholesterol acquired from AC.  
Such activation leads to the upregulation of phagocytic receptors (Mer) and opsonins (Gas6, MFG-8E, 
and C1qb) to facility the continued uptake.   Thus, one possibility is that after engulfing the metabolic load, 





LXR/PPAR.  (2) LXR and PPAR activation increase the expression of the lipid transporter ABCA1 and 
enhance the cholesterol efflux.   The cholesterol content on the plasma membrane is critical to for 
receptor mediated signal transduction.  Thus, another possibility is that UCP2 or DRP1 can regulate 
ABCA1 induction after engulfing corpse, and thus influence the intracellular signal transduction.  (3) It has 
been shown that high-glucose environment reduces corpse uptake.  The ingestion of corpse could affect 
the glucose level in the microenvironment.   DRP1 (UCP2 or ΔΨ) can somehow maintain the glucose 
level in the microenvironment and eventually facilitate continued corpse uptake.   
In conclusion, we discovered a novel and essential role of mitochondria fission in efferocytosis in 
myeloid cells.  Mitochondrial fission could be a potential target to stablize the atherosclerotic lesion or 
























Atherosclerosis is a life-long chronic disease featured by unresolvable inflammation.  It develops 
from the early atheroma formation, through the intermediate stage when the foam cells are covered with a 
“fibrous cap”, toward the advanced lesions that contain huge necrotic core areas.  All these processes are 
significantly determined by monocyte-derived Mφs, the dominant cell type in the atherosclerotic lesions.  
Therefore, the thesis studies focus on exploring different pathological roles of Mφs during both the early 
athergenesis and advanced atherosclerosis. 
Mitochondrion is an interesting organelle beyond its role of generating ATP.  In this thesis, we 
have found two novel functions of mitochondria in Mφs.  The natural byproducts of OXPHOS in 
mitochondria, mitochondrial ROS, exert pro-inflammatory roles through regulating the activation of a key 
transcription factor NF-κB and transcriptional upregulation of an essential chemokine MCP-1.  Through 
this mechanism, mitochondrial ROS in Mφs continuously amplify the chronic inflammation during early 
atherogenesis.  Unexpectedly, we discovered a novel function of mitochondrial dynamic changes in 
regulating the phagocytic capacity of Mφs in the second part of this thesis.   Such cutting-edge discovery 
opens a new area of studies to explore the roles of mitochondrial dynamics in the immune system, in 
particular different immune cells and their unique functions.   
The whole thesis depends on the discoveries using experimental atherosclerosis models, and 
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